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ABSTRACT 
The lack of age-appropriate (paediatric) authorised medicines is a long-standing problem 
amongst regulatory authorities, patients, parents and prescribers. This is driven by the paucity 
of information on clinical efficacy, deficiency in safety data (i.e. biopharmaceutics) and the lack 
of quality information such as palatability and acceptability data in children. To counteract this 
deficiency bespoke, unlicensed formulations are formulated by contract manufacturers, 
hospitals and dispensing pharmacists using a variety of ‘recipes’ and differing manufacturing 
protocols.  
In this work, Morphological Analysis as a problem structuring method is deployed using key 
stakeholders of the problem complex. This method, developed from operational research and 
design thinking sectors, has the ability to structure and parameterise a complex problem to 
isolate a smaller subset of an internally consistent solution space for the design of experiments. 
Hence, Morphological Analysis is used experimentally to decide which pharmaceutical dosage 
forms of furosemide would be selected as a solution space for paediatric patients with low 
cardiac output syndrome. Morphological Analysis application resulted in the selection of two 
different dosage forms for further work (Microemulsion oral liquid dosage form and an Oro-
dispersible Mini-tablet). 
The furosemide microemulsion formulation was developed using ternary phase diagrams to 
isolate the efficient self-emulsification regions. A range of experimental techniques and 
instruments were used to characterise the system such as HPLC, phase stability studies, 
droplet size determination, surface tension measurement, drug-excipient compatibility studies 
using FTIR and NMR, viscosity determination, thermodynamic stability assessment and 
determination of shelf-life via accelerated and long-term stability studies. The optimum 
composition of the furosemide microemulsion consisted of: MCT Oil 14%, Labrasol 60%-
Transcutol-HP 20% (3:1) and Water 6%. 
 III 
A furosemide oro-dispersible mini-tablet formulation (ODMT) was also developed and 
analysed for quality assessment. The development approach for ODMT used factorial design 
at two levels with four factors. Pre-formulation studies included drug-excipient compatibility 
assessment using differential scanning calorimetry and powder flowability evaluation using 
angle of repose and Hausner’s ratio techniques. For that, sixteen batches of ODMTs were 
manufactured using a Manesty F3 tablet press; Post-compression testing and characterisation 
processes were performed and this involved testing for weight variation, hardness assessment, 
friability, in vitro disintegration, wetting time, drug content analysis, dissolution time and 
stability of ODMTs under ICH conditions. The optimum composition of furosemide ODMT was 
found to be (ludiflash excipient + 0.6% magnesium stearate lubricant + 1mg/tablet furosemide 
API) with 10 minutes mixing time at value 19 compression force. 
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 1 
CHAPTER 1 
1.1 Introduction 
The Complexity of Paediatric Formulation Development 
“Children are the world's most important resource”  
Prof. Bonita F. Stanton, 1990, Nelsons Textbook of Paediatrics 
Paediatrics can be considered as the discipline concerned with all aspects of the well 
being of infants, children and adolescents, including their health and physical, mental and 
psychological growth and development and their opportunity to achieve full potential as 
adults. Healthcare professionals and formulators must be concerned not only with 
particular organ systems and biological processes but with overall well-being aspects 
from diagnosing an illness to administering an age-appropriate medicine aiming to 
provide the highest efficacy and lowest possible side effects with the maximum quality 
(e.g. smell, colour, texture and taste) from which have a major impact on the physical, 
emotional and mental health and social well-being of children and their families.1 
One of the most challenging and critical areas in drug development is the pharmaceutical 
formulation of paediatric medicines. Children form a large percentage of patients’ 
population but they have been a neglected group where medicines are concerned. It is 
not that children do not have access to medicines, but that few medicinal products have 
been designed and tested specifically for paediatric use.2  Additionally, children can 
neither be regarded as small adults nor as a homogenous group amongst themselves. 
In fact, there are dramatic changes in physiology and pharmacology during the 
development to maturation meaning that the way children absorb, distribute, metabolise 
and eliminate drugs cannot often be extrapolated between different subsets or from adult 
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clinical data3. This got further complicated by the fact that there has been variation in the 
definition and classification of paediatric age groups between texts and studies. To 
overcome this limitation, the International Conference on Harmonization (ICH) has 
provided an agreed definition to paediatric groups for regulatory purposes (EMA, 2000). 
The definition and classification of age groups in paediatrics when provided was based 
on the major changes in physiological, pharmacokinetic (PK) and pharmacodynamics 
parameters occurring during development as defined in Table 1.   
Table 1: Definition and age ranges of the paediatric population as per ICH4 
Definition Age group 
Preterm newborn infants <37 weeks’ gestation 
Term newborn infants (Neonates) 0 – 27 days 
Infants and toddlers 28 days to 23 months 
Children 2 – 11 years 
Adolescents 12 – 16 or 18, depending on region 
The crucial parameters applied in age-groups classification are discussed in further 
details to emphasise differences between paediatrics and adults and paediatrics 
amongst their different age groups specifically PK parameters for oral administration. 
Additionally, to develop an age-appropriate medicines for children, it is fundamental to 
understand all relevant variables and factors that differ between paediatric age groups 
and adults. Such variables include the pharmacological aspects, palatability and 
acceptability, regulatory requirements, excipients toxicity and commercial aspects behind 
paediatric medicines. In this chapter these variables will be discussed to simplify the 
objectives of the thesis. 
 Firstly, an illustration of the differences in body physiology and clinical pharmacology 
between paediatrics and adults is discussed including the pharmacokinetic and 
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pharmacodynamics changes during the maturation process. 
1.2 Pharmacokinetics Aspects and their Differences between Paediatrics and 
Adults 
Pharmacokinetics term is defined as the study of the kinetics of medicine including its 
absorption, distribution, metabolism and elimination/excretion which can be viewed 
simply as describing what happens to the drug within the body.5 
 In children, pharmacokinetic parameters change through the development and maturing 
processes, altering the disposition of drugs and bioavailability. Bioavailability is 
understood to be the extent and the rate to which a substance or its active moiety is 
delivered from a pharmaceutical form to become available in the general circulation.6  
These changes necessitates carrying out specific studies in the different paediatric ages 
to establish particular dosification steps in the paediatric population.7 
Pharmacokinetic measures, such as area under the curve (AUC) and concentration at 
the maximum (Cmax) are calculated from Absorption, Distribution, Metabolism and 
Elimination (ADME) measures, including clearance, half-life and elimination of a drug 
from the body. Generally, all drugs show inter- and intra-individual variance within bodies 
in pharmacokinetic measures and/or parameters. However, general variations are 
considered very substantial and significant within the different paediatric age groups and 
in comparison with adults. For instance, when administering a medicine, in order to 
achieve AUC and Cmax values in children similar to values associated with effectiveness 
and safety in adults, it is important to evaluate the pharmacokinetics parameters of a drug 
over the entire paediatric age range in which the drug will be used8. Additionally, where 
growth and development are rapid, adjustment in dose within a single patient over time 
may be important to maintain a stable systemic exposure.9 
 4 
Beside the fact that pharmacokinetics aspect are crucial for dosing, ADME data and 
parameters are also essential for a drug to gain licensing approval for paediatric use. 
Table 2 lists some cardiovascular drugs which have not been approved for paediatric use 
with either dosage forms by EMA due to lack of data on their ADME if medicines is taken 
orally, efficacy or safety in children for all routes of administration. 
Table 2: List of some drugs not approved by EMA for paediatric use10 
Medicine 
Approved paediatric 
use 
Needs 
Amiodarone 
 
> 3 years (United 
Kingdom) 
Extension of the indication (efficacy, safety data 
and dose) < 3 years. Lower age limit to be 
defined in children due to iodine intoxication and 
thyroid adverse effects Age appropriate 
formulation (benzyl alcohol in current iv 
formulation) 
Candesartan Not approved 
Extension of the indication (efficacy, safety data 
and dose) to all age groups Age appropriate 
formulation 
Valsartan Not approved 
Extension of the indication (efficacy, safety data 
and dose) to all age groups Age appropriate 
formulation 
Clopidogril Not approved 
Extension of the indication (efficacy, safety data 
and dose) in all age groups Age appropriate 
formulation 
Prazocin Children > 12 years 
Extension of the indication to children < 12 years 
(efficacy, safety data and dose) Age appropriate 
formulation 
Furosemide 
Children (for treatment of 
oedema in Sweden, 
hypertension in France) 
Indications for oedema and hypertension and 
age appropriate formulation to be made available 
in all Member States 
1.2.1 Oral absorption of drugs in paediatrics 
There are several routes of administration used in drug delivery for children, but as with 
adults, the most common and convenient route involves oral administration. A therapeutic 
agent administered by oral route must overcome chemical, physical, mechanical and 
biological barriers to be absorbed and achieve its targeted effect within the patient’s body. 
The oral administration route has numerous factors and variables which can affect the 
drug absorption. These factors and variables include the developmental changes in the 
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gastrointestinal tract (gastric pH, volume and emptying rate)  and at the absorptive 
surfaces in paediatrics which influence the rate and extent of the bioavailability of a 
drug.11 
After oral administration, medicines can also get metabolised by intestinal enzymes 
which exert a large influence on drug absorption and bioavailability as well. For example, 
in neonates, there is underdeveloped enzymes production that causes a delay in the 
absorption rate12. Additionally, the bioavailability of some drugs can be influenced by 
intestinal microflora metabolism (hydrolysis and reductions), which is thereby different in 
infants, children and adults. For example, by two years of age there are bacteria in the 
intestine that are able to metabolise digoxin, however, it is not until adolescence when 
adult levels of metabolism are reached.13 
1.2.2 Distribution of drugs in paediatrics 
Following gastro-intestinal absorption, a medicinal drug is distributed to various body 
compartments according to its physicochemical properties, such as molecular size, 
ionisation constant and relative aqueous and lipid solubility. Several of the processes 
involved in the distribution of drugs are significantly different in neonates and infants 
when compared to adults. Factors including plasma protein binding and water partitioning 
are continuously fluctuating throughout the first few years of life, thus affecting the 
distribution of drugs. These factors are mainly affected by body water/ fat composition. 
There are age-related changes in body composition, protein binding and active transport 
mechanisms14. The most dramatic changes in body composition occur in the first year of 
life but changes continue throughout development towards puberty and adolescence, 
where observed particularly in the proportion of total body fat. This affects water soluble 
molecules such as aminoglycosides as will have a higher volume of distribution in the 
very young age group whilst fat soluble substances, such as diazepam may be expected 
to have their greater volume of distribution in older infants and toddlers where their body 
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fat composition increases in proportion to water.14 
 Plasma protein binding of compounds is another main factor as influential as body 
compositions in distribution of drug. This is dependent upon the amount of available 
binding proteins, the number of available binding sites, the affinity constant of the drug 
towards the protein and the presence of pathophysiological conditions or endogenous 
compounds that may alter the drug-protein binding interaction.15 
1.2.3 Metabolism of drugs in paediatrics 
Of all the body organs, the liver is quantitatively by far the most important site for 
paediatric and adults drug metabolism. At birth, the liver forms 5% of newborn’s body 
weight approximately whereas, it constitutes only 2% of adult body weight16. There are 
numerous factors which can affect hepatic clearance of any medicinal product. These 
factors include blood flow, hepatic enzyme activities (intrinsic metabolism) and plasma 
protein binding, as discussed in the previous section. Blood flow and drug metabolising 
enzymes are considered to be at relatively low level in paediatric at birth and these two 
factors usually require more than one year of age for a child to reach adults rates or even 
slightly less. 
Generally, drug metabolism involves two phases in the liver: phase I reactions such as 
oxidation, reduction and hydrolysis, and phase II reaction such as conjugation with 
glucuronic acid and sulphation. At birth, metabolic enzymes for both phases I and II in 
human liver are mostly immature. The different capacity to metabolise drug in paediatric 
patients may result in lower or higher plasma levels than these reached in adults which 
can cause over- or under-dosing of the intended dose, necessitating dose adjustment 
before administration.17 
In phase I, metabolising oxidative reactions are the most important step, largely mediated 
by cytochrome P-450 (CYP)-dependent. The total cytochrome P450 content in the foetal 
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liver is between 30 and 60% of adult values and only approach adult values by 10 years 
of age18. CYP2C isozymes are barely detectable in newborns due to their very low 
concentration and existence. While, they represent one-third of average adult values one 
month after birth, remain unchanged until one year of age and then increase in proportion 
after that age19. Taking the anticonvulsant phenytoin as an example, in pre-term infants, 
the apparent half-life of phenytoin is prolonged (75h) relative to term infants <1 week after 
birth (20h) or term infants aged >2 weeks (8h).20 To illustrate the variation in half-lives of 
drugs metabolised by CYP450 isoenzymes between neonates, infants, children and 
adults, an example of different medicines’ half-lives is shown in Table 3. 
Table 3: Different half-lives of drugs metabolized by CYP450 isoenzymes21 
Isoenzyme Drug Neonate Infant Children Adult 
CYP1A2 
Caffeine 95 7 3 4 
Theophylline 24-36               7 3 3-9 
CYP2C9 Phenytoin 30-36 2-7 2-20 20-30 
CYP2c19 
Phenobarbital 70-500 20-70 20-80 60-160 
Diazepam 22-46 10-12 15-21 24-48 
CYP3A 
Carbamazepine 8-28 --- 14-19 16-36 
Lidocaine 2.9-3.3 --- 1-5 1-2.2 
 
Phase II metabolic processes are more limited with methylation, acetylation and 
glucuronidation forming the principal types. Like phase 1 enzymes, there is age 
dependency in expression. For example, the activity of N-acetyltransferase, which 
involved in the metabolism of drugs such as hydralazine and isoniazid, is almost three-
fold higher in adults compared to that in the foetal liver cytosol22. Given the enormity of 
this subject, more details on this type of metabolism and of other processes such as first 
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pass metabolism in the gastrointestinal cell wall, will not be described but concluded with 
examples as shown in Table 4. 
Table 4: Isoenzymes activity in paediatric population compared to adults 
 
In summary, it can be concluded that the metabolic variation between paediatrics and 
adults is of major significance as the drug metabolising rate varies significantly with 
children progressing through the 5 ICH age bands. Therefore, the medicinal dosing 
should always be associated with age, requiring adjustment of doses per kg body weight 
after considering the status of the metabolizing capacity. Subsequently, doses should be 
considered carefully in order to achieve equivalent therapeutic concentration and avoid 
any side effect and/ or toxicity caused by metabolic disorder and immaturation. 
1.2.4 Renal elimination of drugs in paediatrics 
In general, medicines are eliminated from the human body either unchanged as the 
parent drug or altered as metabolites. There are various means of drugs excretion and 
kidney is considered the principal organ involved in the elimination of drugs and their 
metabolites. Excretion of medicinal products by kidney is entirely dependent on three 
    Isoenzyme Paediatric activity Drug class Examples 
CYP1A2 ↓ until 2 years Antidepressant, 
Bronchodilator, 
Diuretic 
Duloxetine           
Theophylline             
Triamterene 
CYP2C9 ↓ until 1-2 years Anticoagulant, 
Antidepressant, 
Warfarin                         
Phenytoin 
CYP2C19      ↓until 10 years Antidepressant, 
Benzodiazepine 
Citalopram, Sertraline   
Diazepam 
N-Methyltransferases ↓ until 7-10 years Analgesic Morphine 
N-Methyltransferases ↓ until 7-10 years Antiepileptic, 
Benzodiazepine 
Lamotrigine, 
Clonazepam, 
Lorazepam 
NAT2 
 
↓ until 1-4 years Antihypertensive, 
Anti-infectious 
Hydralazine 
Isoniazid 
 9 
processes; glomerular filtration, tubular secretion and reabsorption. These processes rely 
on renal blood and renal plasma flow which increases with aging as a result of an 
increase in cardiac contraction and cardiac output and a reduction in peripheral vascular 
resistance. 
At birth, renal blood flow in a healthy paediatric is 5 to 6% of cardiac output, compared to 
15 - 25% by one year of age and reaches adult values after approximately two years of 
age23. Therefore, paediatric patients with low cardiac output syndrome (the condition 
studied with its treatment options in this research) at birth develop slower renal filtration 
leading to conditions such as congestive heart failure and oedema which would have 
slower renal elimination as well. Previous studies have shown that during the neonatal 
period, the elimination of many drugs which get excreted in urine in unchanged form is 
restricted by the immaturity of glomerular filtration and renal tubular secretion. Other 
studies show that a similar or greater rate of elimination from plasma than in adults has 
been observed in late infancy and/or in childhood for many drugs including digoxin, 
phenytoin, carbamazepine, levetiracetam, chlorpheniramine and cetirizine24. Therefore, 
larger doses of these drugs (mg/kg) must be administered in children in order to achieve 
equivalent plasma concentrations and efficacy to adults.  
Another factor affecting drug renal elimination is infant urinary pH values as they are 
generally lower than adult values23. In general, urinary pH may influence the reabsorption 
of weak organic acids and bases medicines and differences in renal drug elimination may 
reflect the discrepancy in urinary pH values which leads to variation in efficacy of 
administered drugs. 
1.3 Pharmacokinetic of furosemide in adults and paediatrics 
The preceding section on ADME highlighted the differences that drug in general undergo 
in adults and children. As this thesis will be using furosemide as the model drug in the 
design of age-appropriate formulations, it is pertinent to briefly discuss the differential 
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pharmacokinetic behaviour of furosemide between these two populations.  
There is no data concerning the oral absorption of furosemide in very young children; 
additionally in neonates, furosemide is given via the intravenous route. Furosemide is 
metabolised into an inactive acidic metabolite (2-amino-4-chloro-5-sulfamoyl anthranilic 
acid) and is conjugated with glucuronic acid as a water-soluble entity for renal excretion25. 
However, glucuronyl transferase is poorly developed in children as seen observed from 
mid-gestation human foetal liver and kidney tissue samples. The metabolism of 
furosemide in neonates was studied by Aranda et al (1982).26 Furosemide is metabolised 
into an inactive acidic metabolite (2-amino-4-chloro-5-sulfamoyl anthranilic acid) and is 
conjugated with glucuronic acid to give inactive furosemide glucuronide. Mean fractions 
of the total urinary excretion as unchanged furosemide ranged between 52.5 and 55.6%. 
The mean fractions of total urinary excretion as furosemide glucuronide and acidic 
metabolite ranged from 13.3 to 23.2% and from 20.9 to 29.3%, respectively. 
In adults, average bioavailability of furosemide is 71 ± 35%. In neonates, mean 
bioavailability is 84.3% (range 56% to 106%) and time to peak effect when given 
intravenously is 1 to 3 h. There is a great inter-individual variability in the kinetic 
parameters of furosemide in neonates. The half-life (t½) is 6 to 20-fold longer, clearance 
is 1.2 to 14-fold smaller and volume of distribution (Vd) is 1.3 to 6-fold larger than the 
adult values. 
In adults, renal elimination of furosemide occurs by glomerular filtration as well as by 
tubular secretion via a general organic anionic secretory pathway located in the proximal 
convolute tubule. In neonates, furosemide elimination is decreased because of a low rate 
of tubular secretion, and in infants with very low body weight, filtration is the major route 
of renal elimination. 
Table 5 summarises the pertinent differences in metabolism and elimination of 
furosemide between paediatrics and adults. 
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Table 5:  The main differences in furosemide metabolism and elimination between 
paediatrics and adults 
Variable Paediatrics Adults 
Bioavailability 
Mean bioavailability is 84.3% 
(range 56% to 106%) 
Average bioavailability is 71 
 ± 35% 
Peak time 
Time to peak effect when given 
intravenously is 1 to 3 h 
Peak serum furosemide 
concentrations occur at approximately 
1 to 1.5 hours 
Half Life (t½ ) 
The half-life (t ½ ) is 6 to  20-fold 
longer than adults 
The half-life (t ½ ) is 1.3 h ± 0.8 
 
Clearance 
(mL/h/kg) 
Clearance is 1.2 to 14-fold smaller 
than adults 
Clearance is 99.6 ± 34.8 
 
Volume of 
distribution (Vd) 
(L/Kg) 
Volume of distribution (Vd) is 1.3 to 
6-fold larger than the adult values 
Volume of distribution (Vd) is 0.13 ± 
0.06 
Elimination 
Furosemide elimination is 
decreased because of a low rate of 
tubular secretion, and in infants 
with very low body weight, filtration 
is the major route of renal 
elimination. 
Renal elimination of furosemide 
occurs by glomerular filtration as well 
as by tubular secretion via a general 
organic anionic secretory 
pathway located in the proximal 
convolute tubule. 
 
1.4 Pharmacy Practice as it relates to Paediatrics 
In the medicinal world, adults have better access to licensed medicines that have been 
tested and evaluated for efficacy, safety and quality than paediatrics. According to the 
Department of Health in the UK, in ideal circumstances children and young people should 
have access to licensed formulations which are appropriately evaluated for use in 
children.  However, this is not the case in paediatrics practice as very few medicinal 
products have been designed, tested and licensed specifically for their use leading to 
difficulty in obtaining treatments. Therefore, it is relatively common for children to be 
treated with a medication for which there is no sufficient information in its prescribing 
label called off-label use27. This is currently defined by the Medicine and Healthcare 
products Regulatory Agency (MHRA) in the UK as medicines possessing UK/European 
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marketing authorisation but used outside of the indication(s) specified therein. Further, a 
medicine not possessing UK/European marketing authorisation is called an unlicensed 
medicine28. For instance, medicines authorised by the US FDA but which is imported into 
the UK or Europe.   
1.4.1 Off-label, extemporaneous, unlicensed medicines and special preparations 
When dealing with paediatric patients’ treatment options, it is important to distinguish 
between different types of preparations, not only with respect to regulatory aspects, but 
also with regards to the safety in paediatric settings. These types are explained in more 
details as the following: 
- Unlicensed medicines are medicines administered via unlicensed dosage form 
obtained after manipulation of the original dosage form for example crushing or 
cutting tablets or opening a capsule. These are referred to as extemporaneous 
preparations. Ideally, extemporaneous products should be prepared from the active 
pharmaceutical ingredient (API), but frequently, commercial dosage forms are 
manipulated into a suitable form for administration to children. These preparations 
for paediatrics should usually take place in registered premises such as pharmacies, 
hospitals and health centres. In addition, they must be prepared under supervision 
of a pharmacist or qualified medical officer and in accordance with a prescription for 
administration to a particular patient.  When larger amounts are prepared in bulk, the 
terms ‘specials’ is used. Specials have a similar status but are made in large volumes 
by licensed GMP manufacturers. The license is issued to manufacturers by specific 
national competent authorities (NCAs) such as MHRA in the UK. 2 
- The term off-label medicine refers to any use of an authorised medicinal product not 
covered by the terms of its marketing authorisation. Examples would include using 
medicines for different non-authorised indication or at a different dose or dosage 
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frequency or for a patients group not specified on the label. The decision tree in 
Figure 1 describes the risk benefit of each option. 
Figure 1:  Decision pathway for providing oral doses to children for whom whole 
tablets/capsules are unsuitable 
 
Recent hospital based studies within the European Union show that many drugs used in 
children are either not licensed or are prescribed outside their licensed indications (off-
label). On general paediatric surgical and medical wards, 36% of children receive at least 
one drug that is either unlicensed or off label during their inpatient stay. In paediatric 
intensive care the figure is around 70% rising to 90% in neonatal intensive care settings. 
Another study on children's wards in five European countries found that almost half of all 
prescriptions were either unlicensed or off-label medicines. This suggests that many 
children in hospital are exposed to drugs without the guarantees the regulatory process 
should ensure. There is now evidence that the incidence of adverse drug reactions in 
hospitalised children is higher for unlicensed or off label drugs than licensed 
preparations29. Another study in the United States showed that four out of every five 
children hospitalized are treated with drugs that have never been tested on them and 
outside the hospital one third of all children take such medications 30 . These 
aforementioned studies reinforced the findings of a previous study carried out by Conroy 
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et al (2003), which estimated, depending on the condition, that up to 90% of medicines 
given to children in hospital are not licensed for use in the paediatric population.31 
Unlicensed medicines have not been tested to define safety, efficacy and correct dosing. 
As a result, in a large specific study of children admitted to a paediatric hospital, adverse 
reactions and side effects were associated with 112 (3.9%) of the 2881 licensed drug 
prescriptions and 95 (6%) of the 1574 unlicensed or off- label drug prescriptions (35% of 
all prescriptions). The American Academy of Paediatrics sums up the situations with the 
following statement: “unapproved use does not imply an improper use and certainly does 
not imply an illegal use, but it has been recognised that off-label use and unlicensed 
medicines use is not ideal”.  
In summary, it can be concluded that unlicensed and off-label medicines are not ideal 
option to treat paediatrics and can form major impact on their health. Therefore, it is very 
necessary to develop paediatric-friendly licensed formulations in order to achieve the 
right therapeutic concentration, avoid any side effect and enhance patient’s compliance. 
1.5 Development of Paediatric-Friendly Oral Formulation 
The ICH classification of paediatric population into five distinctive age groups reflects 
biological and physiological changes from birth towards adult maturity. Each of the 
differences and changes discussed previously should significantly impact on the choice 
of oral dosage form which may be used in each subset. In developing paediatric 
formulations, particularly those suitable for newborn and infants, there are issues and 
obstacles encountered concerned with the uncertainty of clinical knowledge with this 
subpopulation. The selection of the dosage form has its constraints on the acceptance 
and ability of administration to paediatrics especially the young ones in order to generate 
compliance and acceptability. Table 6 shows a summary of the preferred dosage forms 
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for drug delivery to different paediatric age groups according to Food and Drug 
Administration (FDA). 
Table 6: Preferred dosage forms for paediatric age groups32 
Age group   Recommended Dosage form 
Newborn 
Has not been identified  
(EMA suggests drops, intravenous and subcutaneous injections and 
suppositories as the oral is not feasible in most cases) 
Infants 
                                               Liquid 
 Small volumes (Syrups, Solutions) 
Children: 2-5 years 
                                               Liquids 
(Liquids and effervescent tablets dispersed in liquids for administration) 
Children: 6-11 
years 
                                                  Solids 
(Chewable tablets, orally disintegrating tablets) 
Adolescents: 12-18 
                                                     Solids 
(Typical adult dosage forms – tablets, capsules) 
 
For instance, six year old children are generally considered the age at which oral solid 
dosage form can be safely swallowed, although this varies based on the child’s 
acceptance14. In addition, the dose volume is a major consideration for the acceptability 
of a liquid formulation. Typical target dose volumes for paediatric liquid formulations are 
≤ 5 ml for children under 5 years and ≤10 ml for children of 5 years and older.  
Palatability and acceptability are another element considered of paramount importance 
in the development of paediatric medicines. For drugs to be accepted by children, they 
should have acceptable taste, smell, colour and texture. Therefore, it is recommended to 
sweeten and flavour paediatric medicines within acceptable limits and to avoid unusual 
flavours and complex taste mixtures in order to increase the chance of formulation 
acceptance by children14. Approaching a specific target paediatric population will also 
affect the flavour as cultural and social factors can have strong influence on children’s 
attitudes and preferences. In general, children usually prefer a higher level of sweetness 
than adults. Additionally, they prefer brightly coloured preparations such as yellow or 
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bright pink colours that are associated with banana and strawberry flavours respectively 
and favourable smells which matches with the flavour if possible. Besides that, paediatric 
patients also prefer a smooth texture, thus the viscosity should be minimised to an 
optimal level in solutions and suspensions by dilution using aqueous diluents, and 
grittiness should be minimised in solid oral dosage forms by using high content of water-
soluble granule diluents.33 
To sum up, there are many important factors to address and consider when developing 
paediatric-friendly age-appropriate dosage form which adds further constraints and 
complexity to paediatric drug development and makes it more difficult to achieve the ideal 
composition and formula. 
1.6 Formulation Design Considerations 
In addition to pharmacokinetic parameters and palatability, excipients form a major 
concern in oral paediatric formulations. These ‘inert’ ingredients are essential in 
formulations to improve solubility, stability, quality and manufacturability. Although, a 
common misconception, excipients can be pharmacologically active34. Certain excipients 
have been found to cause adverse effects on children and particularly in newborns and 
infants due to their underdeveloped physiological characteristics (e.g. metabolism) and 
age-dependent maturation of organ function35 . With regards to adverse effects, the 
addition of preservatives in formulations is seen as one of the main concerns to paediatric 
patients. For example, widely used preservatives such as benzyl alcohol, benzoic acid 
and hydroxybenzoates should be avoided in newborn, infants and children up to 3 years 
old due to their immature metabolism, as they can lead to toxic reactions caused by the 
accumulation of benzoates.14 
Co-solvents, such as propylene glycol, are often used for substances which are not highly 
soluble in water such as diazepam and phenytoin36. However, paediatric patients below 
 17 
four years of age have a limited expression of alcohol dehydrogenases leading to the 
accumulation of aldehyde intermediates and toxic effects which cause depression of the 
central nervous system and nephrotoxicity37. Ethanol is another common example of an 
excipient widely used as a solvent to aid solubility of active pharmaceutical ingredients. 
Studies have found that ethanol may cause adverse symptoms of intoxication, lethargy, 
stupor, coma, respiratory depression and cardiovascular collapse in children.38 
Diluent and filler excipients can also become an issue in some conditions when used as 
excipients in pharmaceutical formulation. As a diluent and/ or filler, lactose is widely used 
in tablets and capsules, in lyophilised powders and as a carrier in dry power inhalation 
pharmaceutical products. Lactose intolerance occurs when there is a deficiency in 
intestinal enzyme lactase in the gastrointestinal tract. This enzyme is normally present in 
high levels at birth, declining rapidly in early childhood to lower levels than required.  With 
respect to sweeteners, aspartame is used as an intense sweetener as it enhances flavour 
systems and can mask unpleasant tastes such as bitterness to improve palatability. In 
literature, a number of adverse events have been reported following the consumption of 
large quantities of aspartame such as hyperactivity in children.38 
In conclusion, it is seen that excipients are not always inert and have associated 
toxicological risks if their intake by paediatric patients exceeds the acceptable daily intake 
(ADI), which is presently not known for all excipients in children). Therefore, WHO has 
indicated the ADI values of some commonly used excipients in paediatric oral dosage 
forms with warnings and restrictions on each type as shown in Table 7. 
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Table 7: WHO ADI values of commonly used excipients in paediatric oral dosage39 
Excipient 
ADI 
(mg/kg/day) 
Warning/Restriction 
Saccharin 5mg Carcinogenic potential (banned in Canada) 
Sucralose 15 None 
Aspartame 40 Phenylalanine source, Phenylketonuria 
Cyclamate 11 
Unconfirmed carcinogenic potential 
Banned in US, permitted in EU & China 
Acesfulme 15 None 
Polysorbate 10 None 
Azo dyes 2.5 Allergenic potential, avoid in children 
Sucrose Not specified Causes dental caries and tooth decay 
1.7 The Need for Pharmaceutical Regulations in Paediatrics 
Licensed paediatric dosage forms, especially liquid formulations, are considered the best 
treatment options for paediatric patients as there is less difficulty in swallowing ensuring 
better compliance40. As described, licensed medicines differ from unlicensed forms in 
their efficacy and safety that is supported by clinical trial data. Generally, unless an illness 
largely affects infants and children, medicines remain unlicensed or not labelled for use 
in paediatric populations. The reasons behind this include a relatively small market size 
for children. This limits the return of investment by causing a potential delay in licensing 
a drug for adults. Consequently and according to Department of Health in the UK (DH), 
almost three quarters of medicines prescribed in neonatal intensive care units are 
prescribed outside of licensed indications. On children’s wards, around one quarter of 
medicines are prescribed outside licensed indications (“off-label”) in the UK and over one 
third of children received at least one of such medicines. As a consequence and for 
illustration purpose, warfarin as an example is not licensed in liquid form and is available 
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as a special but the expense and short shelf life along with the drug’s water solubility 
means that it is usually administered as tablets crushed and dispersed in water. In a 
cohort study of paediatric patients receiving warfarin therapy, children under 1 year took 
significantly longer to achieve the target international normalised ratio (INR), needed 
more tests per month and required more dose changes per month compared with other 
age groups.40 
From a financial point of view, there is also major concern in the cost of special 
preparations due to their short shelf lives, requiring more frequent preparations. In a BBC 
news report “Drugs 'specials' cost NHS £160m”, it was stated that according to internal 
NHS sources, a saving of nearly £72m could be made if all specials were limited to £75 
an item. This would indicate that the cost of specials could exceed that value probably 
because they are often prepared in small volumes due to the stability issues discussed 
previously41. Table 8 shows price list for some special preparations made by Aclardian 
Specials Laboratory in the UK for March 2014. 
Table 8: Price list of some special preparations from a UK licensed lab42 
Product Name Pack Size Price 
Cyclizine oral solution 50mg/ 5ml 100ml £131 
Diaxozide oral suspension 250mg/ 5ml 30ml £115 
Tacrolimus oral suspension 2.5mg/5ml 100ml £162 
Hydrocortisone oral suspension 10mg/5ml 100ml £103 
 
To conclude, all formerly studied problems and issues encountered with unlicensed 
preparations and their consequences were the focus of many drug regulatory bodies 
worldwide. In order to overcome these limitations and problem complexes, drug 
regulations were recently developed and established which aimed on establishing better 
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regulations, recommendations and incentives on paediatric drugs for safer and more 
effective licensed paediatric formulations with higher quality and lower cost. Therefore, 
regulatory bodies have tried to resolve this by bringing appropriate regulations and 
directives to address this situation. On 26 January 2007, the new regulation of the 
European Union (EU) on medicinal products for paediatric use43 came into force to 
improve the availability and access of licensed medicines for paediatrics. Its main 
objectives were to facilitate the development and accessibility of medicinal products for 
use in paediatric populations and to ensure that medicinal products that are used to treat 
paediatric populations are subject to ethical research of high quality. It is worth 
mentioning that the EU regulations came after almost 10 years of US regulations on 
paediatric drugs (initiated by section 111 of the 1997 US Food and Drug Administration 
Modernization Act) which has very similar aims and focus as the EU 44 .  The EU 
regulations have also introduced the key measures and incentives to create and 
encourage paediatric drug development, which include a reward for studying medicines 
for children of 6 months extension to the supplementary protection certificate, in effect 6 
months patent extension for the product including adult use and for the patent medicines, 
8 plus 2 years of data exclusivity on paediatric use of the product for new studies awarded 
via a Paediatric Use Marketing Authorisation (PUMA). These incentives are very similar 
to those in USA but the EU proposal is more robust as it requires the sponsor to market 
the paediatric medicine for the approved indication within 12 months, thus speeding up 
the availability for patients. 
The European Medicine Agency has also set the Paediatric Investigation Plan (PIP) 
which is considered the fundamental instrument of the new regulation related to 
paediatric formulations. A pharmaceutical company that intends to apply for marketing 
authorisation within the EU must submit a PIP that contains detailed information on the 
planned developments and clinical investigations in all subsets of the paediatric 
populations45. According to the EU regulation, the PIP shall specify the timing and the 
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measures proposed to access the quality, safety, and efficacy of the medicinal product 
in all subsets of paediatric population that may be concerned. In addition, it shall describe 
any measures to adapt the formulation of the medicinal product so as to make its use 
more acceptable, easier and safer or more effective for different subsets of the paediatric 
population 46 . Thus, the drug development section in the PIP must include the 
development strategy for age-appropriate formulations as well. A similar legislation has 
also been established by FDA called (Best Pharmaceuticals for Children Act, BPCA).  
1.8 Research Aims 
The aim of this research is to develop age-appropriate paediatric oral 
pharmaceutical dosage forms of furosemide for the treatment of low cardiac 
output syndrome. The problem-structuring approach “Morphological Analysis” is 
applied to address and parameterise the uncertainties encountered in paediatric 
drug development and to isolate key critical paths for the selection in order to 
develop novel paediatric-friendly formulations using stakeholders.  
1.9 Research Objectives 
1.9.1 Uncertainties within paediatric pharmaceutical formulation space 
In the light of the reviewed literature from the preceding sections, significant number of 
variables and problems (or a system of problems) are associated with paediatric 
pharmaceutical development. These variables and problems arise from the lack of 
information in the clinical efficacy, pharmaco-toxicological safety data, concerns with 
excipients selections and the deficiency in access to licensed formulations can all be 
merged under a the term of ’uncertainties’.  
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In developing paediatric formulations, tackling uncertainties often reveals or generates 
unintended consequences such as toxicological effects, under-over-dosing, adverse 
drug reactions and lack of compliance. As such, paediatric drug development is a 
multidimensional problem, ambiguous and strongly stakeholder oriented situation with 
many different competing thoughts. Analysing and modelling such problems presents 
formulators and other stakeholders with a number of difficulties and methodological 
problems. Firstly, many of the factors involved in paediatric formulations are not 
meaningfully quantifiable, since they contain strong physiological, psychological, 
toxicological, practice-based and pharmacological dimensions (also referred to as 
parameters or factors). Secondly, the uncertainties inherent in such problem complexes 
are in principle non-reducible and often cannot be fully described or delineated due to 
the large number of parameters and values (or options) within each parameter. Finally, 
the extreme non-linearity (non-uniformity) of paediatric development factors means that 
literally everything depends on everything else such as co-morbidity, duration of 
treatment and paediatric cultural differences etc. Therefore, an alternative form of 
decision support modelling is required which is rarely used in the natural sciences, 
termed problem structuring methods. These methods, as reported by the Institute for 
Manufacturing (based at the University of Cambridge), are able to address three broad 
types of uncertainties as shown in Figure 2.  
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Figure 2: Elements used to structure a problem47 
 
1. Uncertainties about our working environment (UE):  
This usually requires further information to be gathered. For example, the biological 
effect of a medicine in children and adverse events due to excipients. This 
information can often be obtained from technical expert opinion e.g. healthcare 
professionals, specialists working groups of regulatory agencies etc. 
 
2. Uncertainties about our guiding values (UV):  
This is where clearer policies for overall understanding of the problem are needed. 
This type of information usually relates to the perspectives of other stakeholders 
such as regulators, industry executives and patient support groups. 
 
3. Uncertainties about our choices in related agendas (UR): 
This requires a much broader perspective, which is usually obtained from higher 
level ministerial bodies such as Department of Health and international 
organisations (e.g. EMA, WHO etc.). 
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In designing paediatric formulations the type of uncertainties include the following: 
 Clinical uncertainties such as: 
o Use of potentially toxic excipients such as benzyl alcohol, propylene glycol, 
ethanol etc. 
o Juvenile toxicity studies availability as related to changing ADME in children 
(e.g. appropriate animal models) 
 Quality associated uncertainties such as 
o Practice related (i.e. palatability, acceptability and administration issues e.g. 
nasogastric tube administration) 
o Development of novel dosage forms and devices with attendant stability and 
manufacturing concerns 
1.9.2 Problem structuring methods  
Uncertainties inherent in paediatric drug development can be tackled using problem 
structuring methods (PSMs) which has not been employed in drug development before 
in the design of pharmaceutical formulations. PSMs are a branch of Operational 
Research (applied mathematics for real life problems such as logistics, optimisation and 
scheduling) that provides a more ‘softer’ human-centric approach to address’ messy 
problems’. These methods are designed to achieve to clarify issues amongst a wide 
group of relevant stakeholders, generate group consensus, have the ability to combine 
qualitative and quantitative data and commit the working group to an agreed action plan 
of work. 
In short, PSMs are a collection of participatory modelling approaches that aim to support 
a diverse collection of stakeholders in addressing a problematic situation of shared 
concern. Often the situation is characterised by high levels of complexity and uncertainty, 
where differing perspectives, conﬂicting priorities, and prominent intangibles are the norm 
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rather than the exception.  
In general, there are four main PSMs:  
 Soft Systems Methodology (SSM): SSM was developed by Peter Checkland48 in the 
late 1960’s at University of Lancaster whilst seconded from ICI. As an industrial chemist 
he was puzzled that despite the plant operating at ‘maximum’ capacity it did not always 
achieve optimum production efficiency, which was later attributed to human factors. 
Each stakeholder in the system had an individual worldview of how the plant should be 
running and these confluences of thoughts needed to be disentangled to achieve a 
holistic and consensual approach amongst these actors (aka stakeholders).  Like many 
other systems approaches, SSM is a comparison between the world, as it is, and some 
models of the world as it might be. Out of this comparison arises a better understanding 
of the world ("research"), and some ideas for improvement ("action"); as such the term 
‘action research’ is used for real time intervention. Initial work involves interviews and 
meetings to gain an understanding of the problem situation, which is represented by the 
use of 'rich pictures' of diagrams drawn by the participants as visualised (Figure 3). 
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Figure 3: Example of a rich picture diagram in SMM to describe the problem of 
students’ accommodation49 
 
Systems’ thinking uses the concepts of hierarchy, communication, control, and 
emergent properties to identify 'relevant systems' (drawn by participants as a rich 
picture) which can provide useful insights. The method is particularly useful when 
there are deep divisions as to what is the problem. Since the problem is known in 
paediatric drug development, SSM was not applicable as a PSM in this thesis mainly 
because it is a resource intensive and there is no known software for capturing the 
discussions or transcribing the diagrams. 
 Strategic Choice Approach: Unlike SSM that tries to define the nature of the problem 
as seen through the lens of the various actors in the system, Strategic Choice Approach 
(SCA) is an analytical perspective, based on choice models that focuses on strategies 
for shaping the context of decision-making. Friend and Hickling are the originators of 
the method developed at UCL’s Tavistock Institute in the mid-1960s50. 
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In this method, there are four components: shaping, designing comparing and choosing 
as shown in Figure 4. 
Figure 4: Four components of the strategic choice approach 
 
The shaping mode considers the nature of the problems, their inter-linkages and the 
focus. In the designing mode, one considers the options and how they may be linked to 
form alternative solutions. The comparison mode evaluates these alternatives and the 
benefit-risk profile of each proposed solution. Finally, in the choosing mode criteria are 
developed by the working group to evaluate the alternative solutions (weighted) to yield 
the most optimal solution and the way forward.  
Unlike SSM, rudimentary software is available however it cannot run on modern 
operating systems (i.e. beyond Windows XP). It shares some features with Morphological 
Analysis in that it parameterises the problem and then links the options under each 
parameter using a procedure similar to the cross consistency analysis known as analysis 
of interconnected decision areas (AIDA). However, there remain two important 
differences in that SCA tends to focus on no more than four or five parameters (i.e. the 
decision areas) and three to four options as a maximum. Further differentiating feature is 
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that during the AIDA procedure, criteria are developed and weighted, whereas in 
morphological analysis no such weighing takes place as one is concerned with exploring 
what is possible and not what is probable – the latter requiring some form of probability 
distribution associate with each variable of the problem complex, which usually does not 
exist. SCA gets around this problem by asking the group to make a judgement call by 
using qualitative scales such as the Likert scale. 
 Strategic Options Development and Analysis (SODA): SODA was originally developed 
by Colin Eden at the University of Bath51. This PSM, also known as cognitive mapping, 
uses interview and mental maps (captured as ‘bubbles’ or thoughts) to capture individual 
views of an issue. Group maps are constructed through the aggregation of individual 
cognitive maps then the various paths from the problem to the solution give the options. 
An example of a SODA’s group maps is shown in Figure 5. 
 
Figure 5: Example of group maps in SODA 
 
 
In the group format, the process uses two personal computers, special software, one 
(preferably two) large monitor, blank wall space and flipcharts. It is managed by two 
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facilitators: one to focus on the content and one to guide the process.  A group map can 
become enormously large (several hundred bubbles or thoughts on a single cognitive 
map are not uncommon). In the opinion of the author and his supervisors, SODA was not 
considered an option to tackle the uncertainties in paediatric drug development for 
several reasons. Firstly, this approach results in an output that is not visually appealing 
and is not well received by readers as it displays a complicated problem in a rather 
complicated fashion. Secondly, the method is resource intensive requiring specialist 
software and additional equipment as mentioned above. Finally, the necessity of having 
two facilitators, interviewing individual stakeholders and convening them over several 
plenary sessions was not feasible in terms of logistics, timing and expense.  
 General Morphological Analysis or simply Morphological Analysis (MA) is a method for 
structuring and investigating the total set of relationships contained in multidimensional, 
usually non-quantiﬁable problem complexes. MA was used as the PSM in the research 
described in this thesis and will be described in more detail in chapter 3.  Briefly, it 
involves constructing a series of dimensions of an uncertain problem complex and 
various options within each dimension. As problems with more than three dimensions 
cannot be visualised on a 2-dimensional format, they are simply constructed as a table 
as shown in Figure 6.  MA was selected in this research as it can cover any number of 
dimensions, and allows inclusion of both qualitative and quantitative dimensions. 
Furthermore, the method has seen widespread applications in both social and 
engineering sectors52. 
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Figure 6: Three dimensions and options (cells) in a typological format containing 75 
possible configurations. This can be re-formatted as a table. The blue marked cell (blue 
dot) represents the blue-shaded configuration 
 
1.10 Morphological Analysis 
 “Every problem interacts with other problems and is therefore part of a set of interrelated 
problems, a system of problems…. I choose to call such a system a mess” 
Russell Ackoff, Redesigning the Future, 1974 
 
Typically, typology as a simple structuring method addresses uncertainties by combining 
possible combinations obtained between a few (usually two to three) variables or 
dimensions. Each variable contains a range of values or conditions and each of the 
possible combinations of variable-values in the typological field is called a constructed 
type. As exemplified in Figure 6 in the introduction section, a hypothetical problem 
involving three variables (Price P1, Product P2 and Promotion P3) gives rise to many 
constructed types of solutions. Visually, a typology uses the Cartesian dimensions of a 
physical space to represent the variables (e.g. P1, P2 and P3) with their values containing 
75 cells (5x5x3). However, the number of coordinates that can be represented in 
Cartesian display is limited to three dimensions. Typologies of greater dimensions (4, 5, 
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6 etc.) usually get around this problem by embedding variables within each other. But, 
such formats quickly become very difficult to interpret, prone to errors and add another 
layer of complexity to an already existing complex situation such as the case of paediatric 
drug development. Thus, Morphological Analysis (MA) as a PSM was selected to liberate 
such spatial constraints of 3-dimensional space and allows the researcher to allocate any 
number of dimensions (aka variables). In Addition, it is the first application of its kind in 
the pharmaceutical or drug development field. 
1.10.1 Background to morphological analysis  
MA is a method for structuring and investigating the total set of relationships contained 
in multidimensional, usually non-quantiﬁable problem complexes. MA was first applied to 
the aerospace industry by Fritz Zwicky, a professor at the California Institute of 
Technology in the 1930s and 1940s. Zwicky chose to analyse the structure of jet engine 
technology (amongst other application such as the design of telescopes etc.).  His first 
task was to define the important parameters of jet engine technology, which include thrust 
mechanism, oxidiser, and fuel type.  He continued, in turn, to break each of these 
technologies down into its component parts.  Having exhausted the possibilities under 
each parameter (i.e. dimensional) heading, alternative approaches were assembled in 
all possible permutations: for example, a ramjet that used atmospheric oxygen and a 
solid fuel.  For some permutations, a jet engine system already existed; for others, no 
systems or products were available. Zwicky viewed the permutations representing 
"empty cells" as stimuli for creativity and for each asked, "Why not?"  For example, “Why 
not a nuclear-powered ceramic fan-jet?”53  
Although Zwicky coined the term Morphological Analysis, the technique predates him 
and can be traced back to Ramón Lull (1235-1315), according to Lucien Gerardin54. 
Zwicky was the first to use the technique in modern-day applications.  The primary use 
of MA has been in technological forecasting and new product ideation. Historically, 
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scientific knowledge develops through cycles of analysis and synthesis; every synthesis 
is built upon the results of a proceeding analysis, and every analysis requires a 
subsequent synthesis in order to verify and correct its results. The process of MA is 
composed of the cycles of analysis and synthesis in number of iterative steps. In order 
to perform these steps, the problem space is developed (i.e. analysed) and structured by 
identifying the most important dimensions and underlying options that have an influence 
on furosemide formulation and its administration in paediatrics. This type of analysis will 
be used to assess on the design considerations in the development of an age-appropriate 
furosemide dosage form. 
MA relies on a constructed parameters space, linked by way of logical relationships, 
rather than on causal relationships and a hierarchal structure. Analysing and modelling 
critical conditions in pharmaceutical formulations for paediatrics with different age groups 
having their physiological development presents number of difficult problems and 
uncertainties. Firstly, many of the factors and parameters involved in such conditions are 
not meaningfully quantifiable. Secondly, the uncertainties encountered in the problem 
complexes and issues in paediatric formulations can often not be fully assessed as 
explained previously. 
Therefore, using MA was essential to facilitate a graphical (visual) representation for the 
systematic exploration of a solution space using a combination of literature searches and 
assisted by subject matter experts such as paediatricians, pharmacists, formulators and 
regulators to name a few stakeholders in the problem complex.  
1.11 Furosemide Drug and its Application in the Treatment of LCOS 
Furosemide is a potent loop diuretic classified as class IV according to Biopharmaceutical 
Classification System (BCS) with low solubility and low permeability. It is chemically 
designed as 4-Chloro-2-[(furan-2-ylmethyl) amino]-5-sulfamoylbenzoic acid (Figure 7). It 
is a white or almost white, odourless crystalline powder, practically insoluble in water 
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(10µg/ mL & 73.1 mg/L at 30°C), soluble in acetone, sparingly soluble in ethanol (96%) 
and freely soluble in dilute alkali solutions. It has the molecular formula of C12H11ClN2O5S, 
a molecular weight of 330.7 and melting point of 295°C55.  
Figure 7: Furosemide chemical structure56  
 
Furosemide, an off-patent drug first synthesised in 1962, is primarily used for the 
treatment of oedematous states associated with cardiac, renal and hepatic failure. It is 
also used in the treatment of hypertension and widely used in paediatric patients with low 
cardiac output syndrome (LCOS). LCOS in paediatrics is caused by a transient decrease 
in systemic perfusion secondary to myocardial dysfunction. The outcome is an imbalance 
between oxygen delivery and oxygen consumption at the cellular level which leads to 
metabolic acidosis. In children, LCOS is most often caused by congenital heart disease 
and cardiomyopathy. There are few therapy principal options clinically indicated for LCOS 
treatment such as furosemide, digoxin and dopamine. Furosemide is the most widely 
used agent in cardiac failure and LCOS and for this reason it is included in the WHO’s 
Essential Medicines List for Children.  
However, furosemide’s low solubility and permeability plus the lack of age-appropriate 
oral dosage form for paediatrics is a major problem. Thus, one of the aims of this research 
is to contribute knowledge to the field by using morphological analysis as a decision 
making tool for the development and selection of age-appropriate dosage forms of 
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furosemide and to formulate the dosage forms suggested as solutions by morphological 
analysis. 
1.12 Development of Microemulsion as Paediatric-Friendly Liquid Formulation  
Microemulsion is defined as a system of water, oil and an amphiphile which is a single 
optically isotropic and thermodynamically stable liquid solution57. There are significant 
differences between microemulsions and ordinary emulsions. In particular, in emulsions 
the average droplet size grows continuously with time so that phase separation ultimately 
occurs under gravitational force. Therefore, emulsions are thermodynamically unstable 
and their formation requires input of work whereas a microemulsion droplet tends to be 
more stable. Another major difference is that the droplets of the dispersed phase when 
just formulated are generally larger in an emulsion (>0.1µm) such that they often take on 
a milky rather than a translucent appearance.58 
Microemulsions as drug delivery tool show favourable properties such as spontaneous 
formation without the use of any high-shear equipment, thermodynamic stability (long 
shelf-life), easy formation (up to zero interfacial tension), optical isotropy, ability to be 
sterilised by filtration, high surface area (high solubilisation capacity) which is very 
favourable for low solubility drugs such as furosemide molecule. Another main advantage 
of microemulsions is that they are considered as age-appropriate liquid dosage form 
offering dose flexibility and can be easily administered to children and paediatric patients. 
Microemulsion offer high solubilising potency without using solvents that can be harmful 
to paediatrics such as solution which would require co-solvents such as ethanol and 
propylene glycol. In addition, it has smooth texture with zero grittiness, which forms no 
risk of blocking the nasogastric tube in paediatric treatment.  Microemulsion is composed 
of oil, surfactant, co-surfactant and has the ability to form water-in-oil w/o microemulsion 
when dispersed with aqueous phase under gentle agitation59. The nanosized droplets in 
microemulsion have very high surface to volume ratios what makes them capable to 
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efficiently solubilise the drug. The drug is released in a more reproducible manner, which 
normally becomes less dependent on the GI physiology and the fed/fasted state of the 
patient. However, since the drug delivery system should be mild and biocompatible, the 
choice of excipients can be relatively limited and this will be discussed in further detail. 
1.12.1 Microemulsion’s structure 
Microemulsions are dynamic systems in which the interface is continuously and 
spontaneously fluctuating60. Structurally, they are divided into three types: oil-in-water 
(o/w), water-in-oil (w/o) and bicontinuous microemulsions. In w/o microemulsion, water 
droplets are dispersed in the continuous oil phase while o/w microemulsion is formed 
when oil droplets are dispersed in the continuous aqueous phase. In systems where the 
amounts of water and oil are similar, a bicontinuous microemulsion may result. In all three 
types of microemulsions, the interface is stabilized by an appropriate combination of 
surfactants and co-surfactants by reducing the surface tension between the two phases. 
The mixture of oil, water and surfactants is able to form a wide variety of structures and 
phases depending upon the proportions of these components. Hence, the flexibility of 
the surfactant film is an important factor in this regard. For instance, a flexible surfactant 
film will enable the existence of several different structures like droplet like shapes, 
aggregates and bicontinuous structures and therefore broaden the range of 
microemulsion existence. A very rigid surfactant film will not enable existence of 
bicontinuous structures, which will impede the range of existence.61 
1.12.2 Components of microemulsion formulation 
There are numerous types of oils, surfactants and co-surfactants that can be used as 
components for the formulation of microemulsion systems. However, their toxicity, 
irritation potential and unclear mechanism of action put more restrictions on their 
applications. Generally, formulators must choose materials that are biocompatible, non-
toxic, clinically acceptable, and use emulsifiers in an appropriate concentration range that 
 36 
will result in mild and non-aggressive microemulsions. The emphasis is, therefore, on the 
use of generally regarded as safe (GRAS) excipients within their Acceptable Daily Intake 
(ADI) values.  
Oil Phase 
The oil component influences curvatures by its ability to penetrate and hence swell the 
tail group region of the surfactant monolayer. Short chain oils penetrate the tail group 
region to a greater extent than long chain alkanes, and hence swell this region to a 
greater extent, resulting in increased negative curvature62. There are two types of fatty 
acids that are used as oily phase: 
 Saturated fatty acids (for example, lauric, myristic and capric acid) 
 Unsaturated fatty acids (for example, oleic acid, linoleic acid and linolenic acid). 
The main criterion for selecting the oil phase in microemulsions formulation is that the 
drug should have high solubility in the selected oil. Therefore, lipophilic drugs are 
preferably solubilized in o/w microemulsions. This will minimise the volume of the 
formulation to deliver the therapeutic dose of the drug in an encapsulated form63 or in 
microemulsion oral drug delivery form for paediatric patients. Medium chain triglycerides 
are an example of oily phases in microemulsion formulation. 
Medium Chain Triglycerides (MCT) - Labrafac Lipophile 
Medium chain triglycerides are a medium triacylglycerol of saturated fatty acids with a 
chain length of 6–10 carbons, i.e., hexanoic acid (C6:0, common name carbonic acid), 
Octanoic acids (C8:0, common name acrylic acid) and decanoic acid (C10:0, common 
name capric acid). Sometimes, dodecanoic acid (C12:0, common name lauric acid) is 
included as well64. MCTs are defined a class of lipids in which three saturated fats are 
bound to a glycerol backbone. The only way to distinguish between MCTs from other 
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triglycerides is the fact that each fat molecule in MCTs is between six and twelve carbons 
in length as shown Figure 8. 
Figure 8: MCT chemical structure65 
 
 
 
 
 
 
Unlike Long Chain Triglycerides (LCT), significant absorption of MCT occurs in the 
absence of bile acids and pancreatic lipase rending them more advantageous in 
formulating a bioavailable dosage form. Thus, the uptake and absorption of MCTs is more 
rapid than LCT and hence the intestinal uptake of the API in microemulsion containing 
MCT as an oily phase66. MCTs are oxidized rapidly in the organism and they have very 
low tendency to deposit as a body fat in addition to that MCTs are considered a source 
of abundant and rapidly available energy. These particular physicochemical properties of 
MCTs make it a valuable tool in the dietetic management of a number of disorders of lipid 
metabolism.67 
Surfactants 
The surfactant used in microemulsions must be able to lower the interfacial tension to a 
very small value. This type of excipient also facilitates the dispersion process during the 
preparation of a microemulsion and provides a flexible film that can readily deform around 
the droplets and can be of the appropriate lipophilic character to provide the correct 
curvature at the interfacial region. There are many types of surfactants available such as 
labrafil and labrasol. 
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Labrafil 
Labrafil also known as Linoleoyl macrogol-6 glycerides, Linoleoyl polyoxyl 6 glycerides 
or Corn oil PEG-6 esters with a molecular formula C43H88O10 and a molecular weight 
(765.15282).68 Labrafil if taken orally would be in the form of water dispersible surfactant 
composed of well-characterized PEG-esters and a glycerides fraction. Labrafil is 
primarily used as solubiliser to improve the solubility of active pharmaceutical ingredients 
in vitro and in vivo. Its effect to improve the solubility gives it another property as a 
bioavailability enhancer especially for low solubility drugs. Increased oral bioavailability 
is potentially associated with the long chain triglyceride composition and selective 
absorption of highly lipophilic APIs by the lymphatic transport system reducing hepatic 
first-pass metabolism which enhances the administered API efficacy.  
Labrasol 
Labrasol is another surfactant known by various names such as Caprylocaproyl 
macrogol-8 glycerides, Caprylocaproyl polyoxyl-8 glycerides or PEG-8 Caprylic/Capric 
Glycerides. It is available in a liquid form and can be administered orally as a non-ionic 
water dispersible surfactant composed of well-characterised polyethylene glycol (PEG) 
esters, a small glyceride fraction and free PEG. Labrasol is able to self-emulsify on 
contact with aqueous media forming a fine dispersion such as microemulsions. It is 
mainly used as a solubiliser and wetting agent, to improve the solubility and wettability of 
active pharmaceutical ingredients in vitro and in vivo. It also enhances the bioavailability 
and the increased bioavailability is reported to be associated with strong inhibition of the 
enterocytic efflux transporter (known as P-glycoprotein inhibition).69 Labrasol contains 
polyethylene glycol in a liquid form and most polyethylene glycols are absorbed when 
taken orally.70 
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Co-surfactants 
In most cases, single-chain surfactants alone are unable to reduce the o/w or even w/o 
interfacial tension sufficiently to enable a microemulsion to form71. The presence of a co-
surfactant in a formulation allows the interfacial film sufficient flexibility to take up different 
curvatures required to form microemulsion over a wide range of composition72. If a single 
surfactant film is desired, the lipophilic chains of the surfactant should be sufficiently short, 
or contain fluidising groups (e.g. unsaturated bonds). Short to medium chain length 
alcohols (C3-C8) are commonly added as co-surfactants which further reduce the 
interfacial tension and increase the fluidity of the interface73. Transcutol-HP is an example 
of novel co-surfactant that can be used in microemulsion formulations. 
Transcutol-HP 
Transcutol-HP as a co-surfactant is a high purity solvent and solubiliser for poorly water-
soluble active pharmaceutical ingredients. It’s associated with improved drug 
penetration; permeation and drug depot effect what makes it ideal option for low 
permeable molecules such as furosemide. Transcutol-HP co-solvent is approved as safe 
to use in the preparation and formulation of pharmaceutical products 74 . It has the 
chemical name of Diethylene glycol monoethyl ether and available in a liquid form with 
mild and pleasant odour hydroscopic.75 
1.12.3 Acceptable daily intake values of microemulsion excipients  
The concept of the Acceptable Daily Intake (ADI) for humans was originally developed 
between 1956 and 1962 by the Joint FAO/WHO Expert Committee on Food Additives 
(JECFA) and defined as “an estimate of the amount of a food additive, expressed on a 
body weight basis that can be ingested daily over a lifetime without appreciable health 
risk”.  
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Generally, results from studies in humans, experimental animals and in vitro are used in 
deriving and forming the ADI values. The standard toxicity data set should include acute, 
sub-acute (28-90 days), chronic toxicity and carcinogenicity studies. Combined chronic 
toxicity and carcinogenicity studies are often used in the testing of food additives. The 
toxicity tests also include studies on reproductive toxicity/teratogenicity covering at least 
exposure in utero, neonatally (via mothers milk) and up to weaning. In addition studies 
on metabolism and kinetics (preferably also in humans) as well as short-term in vitro 
studies of mutagenicity/ clastogenicity are required.76  
An alternative method to study excipients intake is the “no observed adverse effect level” 
(NOAEL) principle. NOAEL is determined from the most sensitive study in the most 
sensitive species tested. The NOAEL is thus found by study or observation and is 
expressed as the highest dose level producing no detectable adverse alterations of 
morphology, functional capacity, growth, development or life span. The ADI is usually 
established from the NOAEL by dividing it by a safety factor. When the database is 
considered adequate a factor of 100 is used by default, but may be modified when 
adequate human data are available or based on comparative pharmacokinetic/ 
pharmacodynamics data. In some cases where the database is defective, safety factors 
larger than 100 are used if it is found appropriate to establish a temporary ADI.  
1.12.4 Toxicological aspects of microemulsion excipients 
The use of lipid base oral formulations such as microemulsion is of growing interest and 
particularly in paediatric patients. However, the excipients used in formulating 
microemulsion need to be assessed for safe use especially if paediatrics are the targeted 
patients. For instance and based on previous literature, labrasol and transcutol-HP 
excipients cannot be considered as inert compounds in pharmacology and toxicology 
studies especially if administered orally.   
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Labrasol is classified under the name of Caprylocaproyl polyoxylglycerides. Generally, 
Polyoxylglycerides including labrasol are regarded as non-irritant and nontoxic material77. 
In previous tests, labrasol showed high tolerance and very low toxicity in rats with a LD50 
of 22g/kg as well as led to both the alteration of the membrane permeability and the 
inhibition of the secretory systems in the intestinal epithelium.78  
Transcutol-HP, as a co-surfactant excipient, in early investigations was used as a 
solubiliser and absorption promoter. It has been screened for acute toxicity, influence on 
the behaviour and on the sedative and muscle relaxant properties in mice. Since drug 
safety research is frequently faced with the challenge of the selection of appropriate 
vehicles for use in in-vivo non-clinical safety and toxicity assessment studies with poorly 
water soluble drugs and as the safety profile of Labrasol and Transcutol-HP is not well 
documented with enough knowledge, both Labrasol and Transcutol-HP were tested for 
4 weeks by the oral route in Wistar rats. Both excipients were well tolerated at 
5ml/Kg/day. However, changes in appearance and behaviour were observed from 
10ml/kg/day with volume related incidence, severity and duration. In addition, it was 
summarized that Labrasol and Transcutol-HP as 5ml/kg/day were considered as an 
acceptable level for oral administration use as a vehicle for poorly water-soluble drugs.79 
Medium chain triglycerides (MCTs) are widely used for parenteral nutrition in individuals 
requiring supplemental nutrition and are being more widely used in foods, drugs and 
cosmetics. MCTs are essentially non-toxic in acute toxicity tests conducted in several 
species of animals. MCTs exhibit no capacity for induction of hypersensitivity. Ninety-day 
toxicity tests did not result in notable toxicity, whether the product was administered in 
the diet up to 9375mg/kg body weight/day or by intramuscular (IM) injection (up to 0. 
5ml/kg/day, on rabbits). There was no evidence that intravenous (iv) or dietary 
administration of MCTs adversely affected the reproductive performance of rats or 
resulted in maternal toxicity, foetal toxicity or teratogenic effects at doses up to 4.28g/kg 
body weight/day (iv) or 12,500mg/kg body weight/day (dietary). In addition, the safety of 
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human dietary consumption of MCTs, up to levels of 1g/kg, has been confirmed in several 
clinical trials.80 
1.13 Development of Oro-Dispersible Mini Tablets as Paediatric-Friendly Solid 
Formulation  
When considering dosage forms, tablets remain the most conventional and cost effective 
route of administration for most of medicines. However, approximately, one-third of the 
patients’ population encounters difficulty in swallowing or dysphagia81.  According to 
World Gastroenterology Organisation (WGO), Dysphagia refers either to the difficulty 
someone may have with the initial phases of a swallow or to the sensation that food and/ 
or liquid are somehow being obstructed in their passage from the mouth to the stomach82. 
Consequently, paediatric patients encompass the largest portion of the population that 
demonstrates swallowing difficulty and challenges such as risk of aspiration and choking 
causing asphyxia. As solution to this issue, alternative solid dosage forms have been 
investigated for helping to minimise these difficulties such as orally disintegrating tablets. 
Orally disintegrating tablets were developed as a novel dosage form to play a vital role 
in drug delivery to this unique subset of paediatric patients groups as well as those who 
have an aversion to swallowing tablets in general such as geriatric patients without the 
risk of aspiration. 
Over the past three decades, orally disintegrating tablets (ODTs) have gained more 
attention as a preferred alternative mean of administration to conventional oral solid 
dosage forms such as standard tablets and capsules. According to the European 
Pharmacopoeia (EP), an ODT is defined as tablet that can be placed in the mouth where 
it disperses rapidly before swallowing83. The FDA however defines them as a “solid 
dosage form containing medicinal substances, which disintegrates rapidly, usually within 
a matter of seconds, when placed upon the tongue.84 
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1.13.1 Excipient considerations in oro-dispersible mini tablets 
Oro-Dispersible Mini-Tablets (ODMTs) are small ODTs and the only difference they have 
is their diameter size, usually 2-4mm whereas with conventional ODTs they are usually 
between 6-12mm diameters. When formulating Oro-Dispersible Mini-tablets, it is 
important that the ingredients used in the formulation support and contribute towards a 
rapid release of the drug content, resulting in faster disintegration and dissolution. The 
drug content includes the pharmacologically active ingredients and the excipients. 
Therefore, designing an ODMT formulation requires a unique selection of specific 
excipients.  Each of these excipients has its role towards formulating stable, palatable 
and fast melting tablets and has specific criteria to be considered in selection. For 
example, superdisintegrants are agents to aid the rapid ingress of surrounding water to 
aid the break-up of the solid dosage form. If used at high percentage they can adversely 
affect mouth feel (grittiness) and tablet quality such as low hardness and poor friability.  
1.13.2 The selection ODMT excipients 
One of the principle challenges encountered by formulators is how to design formulations 
that are stable, of high efficacy and safety and support patient compliance. The latter 
consideration is a key factor when it comes to long-term treatment of chronic diseases 
such as LCOS. However, hard-to-swallow and/ or unpleasant tasting tablets and large 
volume oral liquids are known to be key barriers for medication adherence. 
In formulating tablets, flowability, compressibility, hardness, stability and compatibility are 
principal factors to take into consideration. There are some ready-to-compress mixtures 
containing ODMT excipients such as Ludiflash. Ludiflash as an example is a co-
processed excipient with super-disintegrating and palatable properties. Its composition 
supports the quality factors (i.e. processability, palatability etc.) substantially and 
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complies with all leading pharmacopoeia monographs. Ludiflash consists of the 
following85: 
 90% Mannitol  
Mannitol is an excipient widely used in pharmaceutical formulations and food product 
preparations. In pharmaceutical formulations, it is primarily used as a diluent (10–90% 
w/w) when formulating tablets and it gains a particular value since it is not hygroscopic 
and may be used with moisture-sensitive active pharmaceutical ingredients. Mannitol 
is a hexahydric alcohol related to mannose and isomeric with sorbitol. It occurs as a 
white, odourless, crystalline powder, or free-flowing granules and has a sweet taste, 
approximately as sweet as glucose and half as sweet as sucrose and it imparts a 
cooling sensation in the mouth77. It can be used in direct-compression tableting 
formulation for which the granular and spray-dried forms are available or in wet 
granulations where granulations containing mannitol have the advantage of being 
easily dried. Mannitol is commonly used as an excipient in the manufacture of 
chewable tablet formulations because of its negative heat of solution (endothermic, 
hence cooling sensation), sweetness, and ‘mouth feel’. It is also used as a diluent in 
rapidly dispersing oral dosage forms such as (ODMTs). If administered orally, 
mannitol is not absorbed significantly from the gastrointestinal tract, but in large doses 
(more than 10g per dose for a 70kg adult) it can cause osmotic diarrhoea. From a 
chemistry aspect, mannitol’s empirical formula is C6H14O6 and has a molecular weight 
of 182.2. The chemical structure of mannitol is shown in Figure 9. 
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Figure 9: Mannitol Structural Formula86 
 
 
 5% crospovidone 
Crospovidone is an insoluble polymer of N-vinyl-2-pyrrolidone used as a 
superdisintegrant in pharmaceutical tablets 87 . Crospovidone works as a 
superdisintegrant by quickly wicking saliva into the tablet to generate the volume 
expansion and hydrostatic pressures necessary to provide rapid disintegration in the 
mouth, unlike other superdisintegrants, which rely principally on swelling for 
disintegration. When examined under a scanning electron microscope, crospovidone 
particles appear granular and highly porous. This unique porous particle morphology 
facilitates wicking of liquid into the tablet and particles to generate rapid disintegration. 
In addition, crospovidone with its high crosslink density swells rapidly in water without 
gelling thus avoiding the rubbery and grittiness sensation. Gelling is usually observed 
with sodium starch glycolate and croscarmellose sodium superdisintegrants because 
they have a lower crosslink density. In contrast, crospovidone superdisintegrants 
exhibit virtually no tendency towards gel formation, even at high use levels. The 
formerly mentioned disintegrants if used in ODMT and chewable products can result 
in gel with an unpleasant and gummy texture88. Crospovidone disintegrants are highly 
compressible materials because of their unique particle morphology as compared to 
other superdisintegrants which are either poorly compressible or non-compressible.  
The chemical structure of crospovidone is shown in Figure 10. 
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Figure 10: Crospovidone structural formula89 
 
 
 
 
 
 5% Kollicoat SR 30D (polyvinyl acetate) 
Kollicoat SR 30D is a polyvinyl acetate dispersion (Figure 11) stabilised with povidone 
and sodium lauryl sulphate. This dispersion is suitable for the manufacture of pH-
independent sustained-release formulations and consists of about 27% polyvinyl acetate, 
2.7% povidone and 0.3% sodium lauryl sulphate. Kollicoat SR 30D is miscible with water 
in any ratio while retaining its milky-white appearance.77 
Figure 11: Chemical structure of Kollicoat SR 30D90 
 
As with all oral solid doses formulation, a lubricant is essential to prevent adherence of 
granule/powder to punch die/faces and promote smooth ejection from the die after 
compaction. Magnesium stearate (Figure 12) is by far the most extensively used tableting 
lubricant due to its optimal effect and low cost. Lubricants tend to be hydrophobic, so 
their levels (typically 0.3 –2%) need to be optimised and right lubricating proportion has 
to be selected as under-lubricated blends tend to flow poorly showing compression 
sticking problems, weight and content variation, and over-lubricated blends can 
O
OH3C
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adversely affect tablet hardness and dissolution rate (due to the hydrophobic barrier 
around the tablet) causing fraction, cracking and capping respectively.  
Figure 12: Magnesium stearate chemical structure91 
 
 
1.13.3 Available techniques for the formulation of ODMTs 
There are two types of techniques that can be followed in formulating ODMTs. These are: 
 Conventional techniques such as freeze drying, spray drying, moulding, phase 
transition process, melt granulation, sublimation, mass Extrusion, and Direct 
compression.92 
 Patented techniques have been developed and patented on the basis of 
formulation aspects and processes. Each patented technique has its 
characteristics that vary on several parameters like mechanical strength, porosity, 
dose, stability, taste, mouth feel, dissolution rate and overall bioavailability to other 
techniques. Examples include Zydis, Orasolv and Ziplet techniques.93 
1.13.4 Quality-By-Design (QBD) approach in pharmaceutical formulation 
According to the EMA, any medicine needs to be designed to meet (paediatric) patients’ 
needs and to consistently deliver the intended product performance. When QBD is 
applied, the quality target product profile (QTPP) gets established taking into 
consideration the specific needs of the paediatric population users94. QTPP is a major 
shift from the traditional Quality by Testing approach which relies on checking product 
quality against the approved regulatory specifications at the end of manufacturing stream 
at great effort and cost95. The QTPP as a systematic approach to development begins 
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with pre-defined objectives and emphasises product and process understanding and 
process control based on sound science and quality risk management96. This approach 
is particularly relevant to morphological analysis, which defines the overall problem 
landscape before isolating a subset of possible solutions, thereby defining the boundary 
conditions of the experimental work.   
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Chapter 2 
2. MATERIALS AND METHODS 
2.1 The Application of Morphological Analysis in Paediatric Formulation 
Design 
This step of the research was carried out by conducting literature exercise followed by 
speaking with and interviewing subject matter specialists such as paediatricians, 
chemists, clinical pharmacists, formulators, regulators, paediatric nurses and parents. 
Morphological Analysis consists of two phases as described in the following: 
A- Analysis Phase 
Analysis phase involves the identification of dimensions (parameters) mainly 
concerned when using furosemide by paediatric patients alongside with values or 
options of each parameter. Based on the reviewed literature and subject matter 
specialists, analysis phase was performed and the problem space was 
constructed as shown in Table 9. 
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Table 9: Factors and conditions involved in using furosemide in paediatric patients. In this analysis phase, there are 
120,960 possible options in this problem space 
Paediatric 
Age Group 
Indications  
Contra-
indications  
Treatment 
Duration 
Administration 
Concerns 
Problematic 
Excipients 
Dosage form 
Type 
Newborn 
(0-27days) 
O
e
d
e
m
a
 a
s
s
o
c
ia
te
d
 w
it
h
: 
Congestive 
Heart 
Failure 
Hypokalaemia 
Short-Term 
use (Acute) 
Compliance and 
Adherence 
Ethanol/ 
Propylene 
Glycol 
Solution 
Infants 
(28days-
23months) 
Renal 
Disease 
Severe 
Hyponatraemi
a 
Medium-
Term Use  
Large Dosage 
Form Size or 
Volume 
Methyl/ Ethyl 
Parabens 
Suspensions 
Children (2-
6years) 
Hepatic 
Disease inc. 
nephritic 
syndrome 
Hepatic 
impairment  
Long-Term 
Use 
(Chronic) 
Palatability and 
acceptance 
Sugar-
Alcohols 
Microemulsion
s 
Children (7-
11years) 
Pulmonary 
Disease due 
to left 
ventricular 
failure 
Anuria or renal 
failure 
 
Dosing 
Flexibility and/ 
or Accuracy 
Surfactants  
Standard 
Tablet or 
Capsule 
Adolescents 
(12-
18years) 
Peripheral 
Oedema 
Addison's 
Disease 
 
Physiological 
Concerns 
Benzyl 
Alcohol 
Chewable/ 
Orodispersible
/ Wafer 
 Hypertension 
Potassium 
supplements  
  
Propyl/ butyl 
Parabens 
Flexible Solid 
Dosage Forms 
     Benzoate 
Injectable (IM/ 
IV 
     
Sodium 
containing 
excipients 
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The analysis as shown in Table 9 was input into a proprietary MA software (Fibonacci™) 
as shown in Figure 13.  
Figure 13: The morphological field (problem space) of furosemide drug for paediatric 
patients as seen in Fibonacci™ proprietary MA software 
 
For each dimensional heading and option cells underneath, comments and definitions as 
agreed by the subject matter specialists are entered (denoted as a red square symbol).   
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 B- Synthesis Phase 
The ‘synthesis phase’ in MA is also known as the Cross Consistency 
Assessment process (CCA). This step is performed because the 
morphological field of furosemide generates 120,960 possible configurations. 
A configuration is a point in a multi-dimensional space represented as a path 
cutting each axis at the appropriate value. The total number of configurations 
is calculated by multiplying the number of options from each dimensional 
heading (i.e.5x6x6x3x8x4x7). CCA is used to reduce this vast number of 
configurations in the problem space to those which are feasible or not in order 
to generate the solutions space.  
Cross-Consistency Assessment  
CCA is based on examining and assessing the pair wise relationship of options (as shown 
in Figure 14). For instance, a newborn cannot be administered with chewable tablets dosage 
form as this is considered “be a logical constraint” or an incompatibility – this is denoted by 
placing X in the CCA matrix97. These types of judgements are made by subject matter 
specialists or informed by data from the literature as whether the option pair can co-exist98 
or not. Figure 14 displays how the problem space matrix (morphological field) has been 
formatted to generate the CCA matrix and the entry of Xs. When consistency checks are 
performed, internally inconsistent configurations are deducted to form the solution space.99 
The CCA matrix comprises of 73 logical constraints and 52 empirical constraints. The total 
number of pair wise cells evaluated was 1088. [X] Represents a logical constraint, [P] is an 
empirical constraint and [–] is no constraint under all conditions.  An empirical constraint is 
an option that can is possible under some circumstances (unlike X which is impossible). The 
grey shaded cells represent no direct relationship between the two options (i.e. they do not 
impact each other, often referred to as a ‘different universe’ in problem structuring).  It also 
can mean non-redundant, non-overlapping or irrelevant. However, the orthogonal definition 
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also has been extended to this use, meaning the characteristic of something being 
independent (relative to something else).  
Figure 14: The CCA matrix which simply pits each option from its dimension against 
other options derived from other dimensions. This screenshot was taken from the 
Fibonacci MA software 
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Figure 15: The CCA matrix shown in Excel for clarification 
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2.2 Methods and Materials Used in Formulation and In-vitro Evaluation of 
Furosemide Microemulsion 
The studies described in this section aimed to formulate a ready-to-use microemulsion 
of furosemide as an age-appropriate dosage form for paediatric oral administration. 
Before formulating the microemulsion, the ADI values of its components are calculated 
based on paediatric oral administration. In order to calculate the ADI values of 
furosemide Microemulsion’s excipients, previous literature was searched and 
Gattefosse Company (excipients manufacturers) was contacted. As per Gattefosse 
detailed response and data collected, each excipient intended for use in the 
formulation has its ADI value as following: 
2.2.1 Transcutol-HP 
Oral route administration has a NOAEL of 1000mg/kg/day obtained from a 3 months 
oral toxicology study in dogs by Gattefosse in 2007. Based on available toxicological 
data, literature and history of use, Transcutol-HP (Diethylene glycol monoethyl ether) 
can be administrated safely to humans at the following proposed dose levels (Table 
10). 
Table 10: ADI level for Transcutol-HP 
 
Acceptable DAILY INTAKE (ADI) 
(PROPOSED BY GATTEFOSSE) 
Route of Administration PDE (mg/kg/day) PDE for 1 adult, 60kg 
(mg/day) 
Oral 10 600 
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2.2.2 Labrasol 
According to Gattefosse, labrasol can be administered safely to humans by oral route 
at dose levels up to 1800mg/ day (Table 11). 
Table 11: ADI level for labrasol 
 
Acceptable DAILY INTAKE (ADI) for Labrasol 
 
Route of Administration ADI (mg/kg/day) ADI for 1 adult, 60kg 
(mg/day) 
Oral 30 1800 
ADI based on a safety factor of 100 and NOAEL of 3000mg/kg/day 
2.2.3 Labrafac (Medium Chain Triglycerides) 
Based on available toxicological data, literature, history of use and manufacturer data, 
labrafac has no toxicological effects reported and is considered safe. Therefore, it has 
no limits to volume administered per day.  
2.3 Solubility Screening 
Solubility screening test was conducted in order to choose the right surfactant (labrasol 
and labrafil) with optimal solubilising ability of furosemide API. The test was performed 
by taking an equal volume of both surfactants and saturating each sample with 
furosemide API. Both mixtures were mixed using vortex mixer and sonicated then left 
for enough time to solubilise the maximum concentration of the drug. Thereafter, both 
samples were filtered, diluted and analysed for quantitative purpose to assess their 
solubilising capacity using HPLC. 
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2.3.1 Materials and reagents used in solubility screening test 
Furosemide active pharmaceutical ingredient was bought from Sigma-Aldrich 
suppliers Company. Labrafil and labrasol surfactants were provided by Gattefosse 
pharmaceutical manufacturers and suppliers. The reagents used for the experiment 
were of high purity and with analytical grade. Stock solutions and aliquots of the 
furosemide API were prepared in methanol at room temperature. The water used in 
mobile phase preparation was double-deionized water and Fresh working solutions 
were prepared daily. Furosemide API was dissolved with two equal volumes of labrafil 
and labrasol surfactants till saturation and the mixtures were degassed by sonicating 
them for half an hour and filtered using syringe filter before injection. 
Apparatus 
The analytical separation and quantification processes of the method were performed 
with HPLC system. The HPLC system was Dionex ultimate 3000 at LPG-3400A 
quaternary pump, VWD-3100 UV detector and a dimension 15X4.6 mm column with 
Eurospher ACE5 C18 packing. The sample injection was manual, the operating 
software was Chromeleon and the separation was carried out at room temperature. 
Chromatographic conditions 
The mobile phase used was H3PO4 (0.5% in aqueous solution) – Methanol (60:40) and 
the pH of the H3PO4 (0.5% in aqueous) mobile phase was adjusted to 3.2 with 
orthophosphoric acid. The analysis was carried out under isocratic conditions H3PO4 
(0.5% aqueous) – methanol using flow rate of 1ml per minute at room temperature with 
equilibrating time set to 5 minutes. Chromatograms were recorded at 236nm using 
VWD-3100 UV detector and the total run time was for 15 minutes. Injector with 20µl 
sample loop introduced the samples into the HPLC machine. 
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Analytical procedure 
Three millilitres of each selected surfactant (labrafil & labrasol) were added into glass 
vial containing excess amount of furosemide (510mg/vial). Both vials were sealed and 
mixed for 10 minutes with the help of vortex mixer and placed into sonication bath for 
half an hour at 35°C temperature to optimize the dispersion and dissolution of 
furosemide API into each surfactant. The vials were then foiled to avoid light 
degradation as furosemide is photosensitive molecule and left for one week to pseudo-
equilibrate prior to HPLC analysis. After one week a fresh standard stock solution of 
furosemide API was prepared by weighing 25 mg of furosemide standard and 
transferring it into 25ml volumetric flask; around 15ml of methanol (mobile phase) was 
added to the content in volumetric flask and sonicated for 10 minutes for complete 
solubility then made up to volume with methanol to obtain a final concentration of 1mg/ 
ml of furosemide standard. From the stock solution, the aliquots of desired 
concentration of furosemide stock solution were prepared by six serial dilutions 
(50µg/ml, 100µg/ml, 150µg/ ml, 200µg/ml, 250µg/ml, 300µg/ml). The mixture of each 
vial was then filtered prior to injecting using Nalgene 0.45µm syringe filter to obtain 
clear filtrate for HPLC injection. Although the filtrates were of high purity, they had high 
viscosity due to the oily nature of these surfactants and the high concentration content 
of furosemide. Each filtrate was diluted with a compatible solvent, for instance, labrasol 
was diluted with 5ml of methanol and labrafil was diluted with chloroform. The pH of 
mobile phase was adjusted with orthophosphoric acid using pH meter. Mobile phase 
was then fitted in the HPLC machine and 20µl of each standard was injected to obtain 
the calibration curve. After calibration was obtained, 20µl volume of each diluted 
surfactant filtrate was injected and the injected samples were chromatographed under 
above conditions and chromatograms were obtained. 
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2.3.2 Method development 
The aim of the method development was to develop a rapid and accurate HPLC 
method for the quantification of dissolved furosemide API into two different surfactants 
for solubility screening purpose using easily available reagents. Prior to the 
chromatographic method development, the detection wavelength was determined by 
obtaining the UV spectrum of furosemide reference solution in order to identify λmax 
which was determined at 236 nm wavelength. 
The chromatographic detection was investigated at 236 nm wavelength using different 
mobile phases consisting of acetonitrile, methanol, H3PO4 (0.5% aqueous) and double-
deionised water on C18 column. The mobile phase was chosen only after numerous 
trials in order to achieve good results with clear and sharp peaks. For instance, a 
composition of acetonitrile and water (50:50) mobile phase with their normal pH was 
applied to the method. No resolution was produced and the results weren’t clear as 
acetonitrile interfered with the furosemide peak and has left doubled-headed peak with 
tailing due to the pH value and column affinity. A trial with methanol and water (50:50) 
mobile phase with pH adjusted to 3.2 reduced the peak interference with the mobile 
phase. However, elution time was short, the peak was tailed and there was obstructing 
solvent peak observed. Water mobile phase was applied as 60% initially and the 
analysis was performed under isocratic elution condition using a flow rate 1ml/ min at 
room temperature. Unfortunately, the solvent peak was still visible and the furosemide 
peak was not sharp enough. Further trials with H3PO4 (0.5% aqueous) and methanol 
were made under isocratic conditions. Under these modifications better peak was 
observed and longer elution time was achieved. 
Again, the furosemide API peaks were saturated. This was obviously due to the high 
concentration of the furosemide API dissolved in both surfactants. Appropriate 
solvents were used to dilute each of the surfactants to reduce the concentration to be 
within the detectable limits and to reduce the viscosity of the surfactants as high 
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viscosity was another concern before injecting into the column. Initially methanol was 
used to dilute both surfactants; it formed a good diluted clear solution by mixing it with 
labrasol filtrate. However, it was immiscible with labrafil filtrate and formed a white 
cloudy and turbid mixture of two different colours as white drops in bright yellowish oily 
phase. After trying different solvents, chloroform was found to be the most miscible 
and compatible solvent, forming an injectable, clear and less viscous solution with 
labrafil filtrate. Using these specifications on the C18 column, the retention time of 11:71 
minutes was reliably produced. 
2.3.3 Phase diagram construction for furosemide microemulsion 
Ternary Phase Diagram was constructed to identify the efficient self-emulsification 
region for furosemide microemulsion. With the help of CHEMEX software, the pseudo-
ternary phase diagram of medium chain triglycerides (MCT) oil, surfactant: co-
surfactant (Labrasol:Transcutol-HP) and water was developed. Ternary phase 
diagram represents the equilibrium between the various phases that are formed 
between the three components, as a function of temperature100. This was developed 
using water titration method and the pseudo-ternary phase diagrams were constructed 
at three different ratios of surfactant/co-surfactant (Labrasol:Transcutol-HP) mixtures 
[S/Co-S= 1:1 (v/v), 2:1 (v/v) and 3:1 (v/v)] in order to identify the self-emulsifying 
regions. Firstly, the mixtures of MCT oil, surfactant and co-surfactant at certain volume 
ratio were prepared in the presence of furosemide 10mg/ ml. Then, these mixtures 
were diluted with water in a drop wise manner using burette till a translucent and 
homogenous mixtures contain furosemide were formed under constant mixing using 
magnetic stirrer as shown in Figure 16. 
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Figure 16: W/O Microemulsion formulation using dropper and magnetic stirrer 
 
 Finalised Method of the Preparation of Furosemide Microemulsion 
Furosemide microemulsion with fixed ratio of surfactant: co-surfactant (3:1) was prepared after 
series of trials to select the optimum ratio of oil, surfactant: co-surfactant and water. In all 
formulations, the concentration of furosemide was chosen to be 10mg/ml. This concentration 
allowed the maximal amount of furosemide to be contained in an age-appropriate dose volume 
for young children and infants.  The formulation methods was performed as the following: 
1) Furosemide API was dissolved in the surfactant using hot plate and magnetic stirrer. 
2) Medium chain triglycerides oil (MCT) and Transcutol-HP co-surfactant were mixed 
together using gentle agitation via the vortex mixer. 
3) The two mixtures from steps 1 and 2 were mixed together by gentle stirring at room 
temperature until furosemide was completely dissolved and a stable, single phase was 
formed.  
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4) Water was then added to mixture in drop wise manner using a burette under 
continuous stirring condition via a small magnetic stirrer until a clear and transparent 
mixture was formed.  
5) The mixtures were then poured into child resistant amber coloured glass bottle as 
furosemide is light-sensitive and the preparation was stored at room temperature. 
 Methods of Characterisation and Evaluation of Furosemide Microemulsion 
2.3.4 Drug content analysis using RP-HPLC 
100µl of the prepared furosemide microemulsion equivalent to 1 mg concentration was diluted 
in chloroform (compatible solvent) and mixed well using vortex mixer before analysis. The 
diluted sample of furosemide microemulsion was then filtered and injected after serial standard 
dilution injections for calibration were collected using RP-HPLC. The sample injection was 
manual and the separation was carried out at room temperature. A mobile phase of phosphoric 
acid (0.5% in aqueous) with methanol was pumped under isocratic conditions at a flow rate of 
1ml per minute. A 20µl volume of each dilution was injected into the column and the effluent 
was monitored at 236nm detecting wavelength. 
2.3.5 Phase separation study  
0.05 ml of furosemide microemulsion was added to 5ml mixture of 0.1N HCL and distilled 
water mixture in a clear glass test tube. The tube was inverted 4 times up and down then left 
to observe any phase separation. Thereafter, the sample was monitored visually for any phase 
separation every hour for 6 -15 hours.  
2.3.6 Droplet size determination of furosemide microemulsion 
The size distribution of droplets formed in the microemulsion after dispersing the aqueous 
phase into the oily phase was measured with Zetasizer (Malvern) at 25°C. Zetasizer 
instrument detects particles and droplets sizes using Dynamic Light Scattering (DLS) of a laser 
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beam at 633 nm wavelength. DLS measures Brownian motion and relates this to the size of 
the particles by illuminating the particles with the laser and analysing the intensity fluctuations 
of the scattered light.  
2.3.7 Viscosity determination of furosemide microemulsion 
The viscosity of furosemide formulation was determined using HAAKE Viscometer C. Spindle 
number 3 was used for the test at 100 rpm and the viscosity was measured in centipoise (cP) 
unit twice (at 0min & 30min).  
2.3.8 Dynamic surface tension measurement 
This test was conducted in order to evaluate the influence of surfactant on reducing the surface 
tension formed between the two immiscible phases (water and oil). The surface tension (ST) 
was determined by Attension Theta Optical Tensiometer at 25°C using hooked needle method 
by passing aqueous droplet into dispersant filled quartz cuvette as seen in Figure 17. 
Figure 17: Droplet shape through hooked needle into dispersant 
 
 
The examinations were performed on the day of preparation and one week after later.  
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Water/ MCT Oil Surface Tension 
The test was carried out on the aqueous droplet into MCT oil dispersant phase before adding 
the surfactant to the oily phase in order to determine the formed surface tension value.  
Water/ Oil and Surfactant Surface Tension 
At this stage, MCT oil was mixed with Labrasol surfactant at the right proportion forming 
dispersant and the water droplet was inserted into the dispersant phase using hooked needle 
technique and the surface tension value was measured. 
2.3.9 Furosemide microemulsion conductivity measurements 
Conductivity measurement was conducted to monitor percolation or phase inversion 
phenomena of furosemide microemulsion. Percolation is often referred to transition of isolated 
water droplets to an interconnected bi-continuous structure (phase inversion)101.  Electrical 
conductivity “σ” was measured using Jenway 4510 conductivity meter at ambient temperature 
(228/°C) as a function of water content (H2O %) for MCT oil and S/Co-S mixture. In general, 
the electrical conductivity of water is very high (7μS) compared to that of MCT oil and labrasol 
surfactant.  
2.3.10 Drug-excipient compatibility studies using ftir 
In order to assess the stability of furosemide and evaluate any interaction might occur between 
the API and microemulsion excipients. Pure furosemide powder and the microemulsion 
mixture were run using FTIR spectroscopy and the spectra for both samples were collected 
for compatibility assessment.  
2.3.11 Furosemide drug-excipients compatibility studies using NMR 
Nuclear magnetic resonance spectroscopy (NMR) was selected as an alternative method to 
FTIR in order to validate the stability of microemulsion and ensure the compatibility between 
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furosemide and other microemulsion excipients. The NMR spectrum of furosemide API was 
obtained after dissolving it in acetone using Bruker NMR. The microemulsion mixture was 
diluted using acetone as well and the both spectra were collected for analysis purpose.  
2.3.12 Visualisation of furosemide microemulsion using light microscopy 
A sample of the prepared microemulsion was analysed visually using an Olympus IX81 
microscope. The micelles or droplets seemed very well distributed and integrated into the 
whole texture of the formulation. In order to visualise the aqueous phase dispersion onto the 
oily phase of furosemide microemulsion, deionised water was again added drop wise to a 
freshly prepared sample of the microemulsion and the sample was stirred continuously using 
magnetic stirrer. Straight after, the sample was scanned with microscopy at 20, 40 and 60x. 
2.3.13 Temperature stability studies 
The objective of the thermodynamic stability test was to evaluate the effect of temperature 
variation on the furosemide microemulsion formulation. Furosemide microemulsion was 
centrifuged at 15,000 rpm for 15 minutes and the formulation was then investigated visually 
for any phase separation. Furosemide microemulsion was also subjected to freeze-thaw cycle 
(-20°C for 3 days followed by +40°C) for 2 days. The sample was then observed visually to 
assess the stability of microemulsion to withstand different temperatures and the ability of its 
spontaneous emulsification property through these temperature cycles.  
2.3.14 Palatability testing 
Palatability is one of the main important elements that contribute toward patient drug 
acceptance and compliance. It’s defined as the overall appreciation of a medicine towards its 
smell, taste, aftertaste and texture102. Therefore, palatability assessment was a prioritised test 
for microemulsion. From testing regime, there are two types of tasting drug palatability, in vivo 
and in vitro testing. In vivo testing required an ethical approval and had many constraints; 
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therefore it was not performed in this research. Instead, in vitro testing using E-tongue was 
planned tried. 
2.3.15 Shelf life 
According to the International Conference on Harmonization (ICH), the purpose of stability 
testing is to provide evidence on how the quality of an active pharmaceutical ingredient such 
as furosemide or a pharmaceutical formulation such as microemulsion varies with time under 
influence of a variety of environmental factors such as temperature, humidity, and light. This 
is often designed to establish a re-test period for the active pharmaceutical ingredient or a 
shelf life for the medicinal product and recommended storage conditions.103 The stability 
testing and shelf life recommendations of ICH were followed in this test and both Accelerated 
and long-term shelf life studies were conducted on the furosemide microemulsion formulation. 
Stability studies under stress temperature conditions 
In regards to the accelerated studies, microemulsion preparations were kept for 0-60 days at 
temperature 30, 40 and 50°C and the formulation was assayed to quantify the amount of the 
furosemide and to assess if any degradation occurred under the stress conditions. Serial 
dilutions from furosemide reference stock solution were prepared and calibration curve was 
plotted after areas of injected aliquots were recorder. Once calibration was obtained, 20 µl of 
furosemide microemulsion was injected after diluting it with chloroform and filtering the diluted 
sample. The chromatograms of each sample exposed to stress conditions were collected and 
analysed for quantity and purity purposes. 
Long term stability studies 
Furosemide Microemulsion was left at room temperature in an amber glass container for 12 
months and the content was analysed again for stability and degradation studies using HPLC.  
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2.3.16 Long Term Phase Separation Study 
Phase separation and precipitation were inspected after 12 months of furosemide 
microemulsion preparation in order to evaluate its phase and content stability and dissolvability. 
A 5ml mixture of 0.1N HCL and distilled water was prepared and 0.05 ml of furosemide 
microemulsion was added to the mixture in glass test tube. The tube was inverted four times 
up and down then left to observe any phase separation. The sample was then monitored 
visually for any phase separation every hour for 6 continuous hours.  
2.3.17 Long term viscosity determination of furosemide microemulsion 
The viscosity of furosemide microemulsion formulation was measured again after 12 months 
of preparation and storage on shelf at room temperature. This test was conducted in order to 
evaluate any texture changes which may have an effect to the formulation viscosity. The 
measurement was carried out using HAAKE Viscotester C and spindle number 3 was used 
for the test at 100 rpm.  
2.4 Materials Used and Methods Followed in Formulation and Evaluation of Furosemide 
Oro-Dispersible Mini Tablets 
In order to implement the QbD system and based on QTPP, the Critical Quality Attributes 
(CQAs) of the product was identified as well as the formulation and process parameters that 
may affect the attributes of furosemide ODMTs dosage form. QTPP is divided into two parts: 
Target Product Profile (TPP) which embodies the overall objectives of safety and efficacy of 
(furosemide) pharmaceutical development program and Target Product Quality Profile (TPQP) 
which involves the performance attributes and specifications that furosemide ODMT should 
possess. The QTPP, quality attributes and criticality for furosemide ODMTs listed are in Table 
12. 
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Table 12: QTPP of furosemide ODMT’s 
Attributes 
QTPP 
Criticality 
TPP TPQP 
Drug-excipient 
compatibility 
Stable 
No interaction 
should occur 
Compatibility is assured, for 
example ,by using DSC 
Dosage form 
Orodispersible Mini-
tablet 
ODMT 
(<40seconds), 
Dissolution (not less 
than 90%  in 20 
minutes in pH 6.8 
buffer medium) 
Ensures complete dispersion, 
release of furosemide drug, 
efficacy and ease of 
administration 
Appearance 
Uncoated tablets 
 
Immediate-Release 
(IR) Round tablets 
Smooth texture without any 
cracks  
Strength 2mg and 5mg 
Identification 
(positive), Assay 
(±5%), content 
uniformity 
(complies) 
content uniformity of analysis as 
determined by the European 
Pharmacopeia (Ph. Eur) 
Route of 
Administration 
Oral 
Palatable to 
paediatrics 
Acceptability and palatability to 
the paediatric population 
Proposed indication 
Treatment of Low 
Cardiac Output 
Syndrome 
Dissolution, 
bioavailability and 
bioequivalence to 
any existing 
products 
Ensure therapeutic efficacy 
Mechanical Strength To be determined 
Sufficient to ensure 
good handling 
stability and short 
disintegrating time 
Ensures good post-compression 
performance balanced by 
complete dispersion 
Impurity To be determined 
Quality to meet 
International 
Conference of 
Harmonisation 
(ICH) Q3B and Q6A 
regulatory 
guidelines 
Safety is assured by controlling 
any impurity using HPLC after 
identifying limits of impurity based 
in qualified toxicological studies.  
Packaging Blister packaging 
Enough to prevent 
environmental 
humidity and 
breakage during 
handling 
Stability is assured by HPLC 
and/or FTIR and visual inspection 
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After designing the performance objectives and quality attributes, the practical part of 
formulation was performed based on factorial design at 2 levels and the methods applied in 
evaluation of ODMTs formulations are as described in the next sections. 
Factorial design at two levels 
Factor (variable) 1: Formulation Strength (amount per each ODMT): 
Level1: (-) 1mg and Level2: (+) 3mg 
Factor (variable) 2:  lubricant (magnesium stearate) concentration per ODMT: 
Level1: (-) 0.3mg % and Level2: (+) 0.6mg % 
Factor (variable) 3: Mixing time 
Level1: (-) 5min and Level2: (+) 10min 
Factor (variable) 4: Compression force 
Level1: (-) 18 compression force and Level2: (+) 19 compression force                       
Note: Manesty F3 (tablet machine) had empirical compression force with no unit. 
16 different batch designs or runs were thus developed as shown in Table 13. 
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Table 13: Factorial design of furosemide ODMTs formulation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.4.1 Formulation technique followed in furosemide ODMTs preparation 
To formulate furosemide ODMTs, direct compression method was followed. Direct 
compression is considered by far the most common and simple technique that usually involves 
the use of conventional pressing equipment, commonly available excipients and a limited 
number of processing steps making it a time saving and cost effective tablet manufacturing 
technique.  
Batch  
Number 
1 2 3 4 
1 _ _ _ _ 
2 + _ _ _ 
3 _ + _ _ 
4 + + _ _ 
5 _ _ + _ 
6 + _ + _ 
7 _ + + _ 
8 + + + _ 
9 _ _ _ + 
10 + _ _ + 
11 _ + _ + 
12 + + _ + 
13 _ _ + + 
14 + _ + + 
15 _ + + + 
16 + + + + 
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Initially, placebo batch (control batch with no API) was formulated to estimate the average 
weight of ODM tablet using Ludiflash mixture. Once the weight was evaluated, the excipients 
(Ludiflash and magnesium stearate) were weighed in the right proportions/ratios according to 
the established factorial design and mixed thoroughly with the addition of furosemide API. The 
final powder mixture was then compressed using Manesty F3 single punch machine with 
custom-made 3mm diameter punch and die station. However, a full pre-compression 
characterisation was carried out before each formulation in order to evaluate the fluidity and 
compressibility of the mixed powder before compression. In addition, a Quality by Design 
approach was applied to pre-define the quality parameters. 
2.4.2 Preliminary work to establish process parameters (pre-formulation studies) 
2.4.3 Drug-excipient compatibility studies 
These studies were conducted to determine any physical and/or chemical interaction that 
might occur between furosemide and formulation excipients. The compatibility of furosemide 
with excipients chosen to formulate ODMTs was evaluated using Differential Scanning 
Calorimetry (DSC-60, Shimadzu, Japan) instrument. DSC is a thermo-analytical technique 
that measures the difference in heat flow rate (mW = mJ/sec) between a sample and inert 
reference as a function of time and temperature104. Furosemide has a polymorphic form and 
it exists in two forms usually. A Polymorphism is the ability of solid materials to exist in two or 
more crystalline forms with different arrangements or conformations of the constituents in the 
crystal lattice105. These polymorphic forms of a furosemide drug differ in the physicochemical 
properties which have an effect on its stability and compatibility with other chemicals. Using 
DSC, each excipient was analysed individually then samples of furosemide drug-excipients 
were prepared in 1:1 ratio and analysed. Individual samples of (drug - excipient) were weighed 
to 5mg in the DSC aluminium pan. The sample pan was then crimped for effective heat 
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conduction and scanned in the temperature range of 25-300°C. Heating rate of 20°C/ min was 
used and the thermogram obtained was analysed for any evidence of any interaction.  
2.4.4 Production of a preliminary batch of furosemide ODMTs  
This batch included the following parameters developed by aforementioned factorial design at 
two levels: 
Run 1 _ _ _ _ 
 
1: Furosemide strength                                                        1mg                       
2: Magnesium stearate concentration                                  0.3mg                     
3: Mixing time                                                                        5min                       
4: Compression force                                                            18N 
2.4.5 Powder flowability tests 
The fluidity of powder mixtures of furosemide API and excipients is crucial towards a 
successful ODMT formulation. Poor powder flowability largely influences the tablet 
characteristics such as: content uniformity, inconsistent hardness, varying in disintegrating 
time and dissolution rate. There are several tests to characterise powder flowability and 
compressibility and the most frequently employed methods are the one followed in this 
research.  
 Angle of repose ()  
Angle of repose was determined using funnel method where the blend of the final 
powder mixture intended for compression was poured through funnel until a maximum 
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pile height (h) was obtained. Radius of the heap (r) was measured and the angle of 
repose value was calculated using the formula:  
= Tan -1 (Height/ radius) 
Flow properties as defined by the EU Pharmacopeia are shown in Table 14. 
Table 14: Flow properties for angle of repose106 
Flow Property Angle of Repose 
Excellent 25 - 30 
Good 31 - 35 
Fair - aid not needed 36 - 40 
Passable - may hang up 41 - 45 
Poor - must agitate, vibrate 46 - 55 
Very poor 56 - 65 
Very, very poor > 66 
 Compressibility index (Hausner’s ratio) 
Hausner’s ratio is an indirect index of ease of powder flow. It’s applied to measure the 
bulk density, size and shape, surface area and cohesiveness of materials by 
determining the flowability of the powder. It is calculated using the ratio: Tapped 
Density/Bulk Density = Pt / Pd. These parameters were calculates as the following: 
o Bulk density (Pd): apparent bulk density was determined by pouring the powder 
mixture of ODMT into a graduated cylinder. The bulk volume (Vb) and weight of 
powder (M) were determined. The bulk density was calculated using the following 
formula: Pb= M/Vb 
o Tapped density (Pt): the plastic measuring cylinder containing known mass of ODMT 
blend was tapped to solid surface for 750 taps within a fixed time. The minimum 
volume Vt occupied in the cylinder and weight (M) of the blend was measured. The 
tapped density was calculated using Pt= M/ Vt 
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                         Table 15: Flow properties for Hausner’s ratio 
Flow character Hausner’s ratio 
Excellent 1.00 - 1.11 
Good 1.12 - 1.18 
Fair 1.19 - 1.25 
Passable 1.26 - 1.34 
Poor 1.35 - 1.45 
Very poor 1.46 - 1.59 
Extremely poor > 1.60 
2.4.6 Post-compression evaluation and characterisation tests 
This involved a variety of tests. Each one is described below: 
Weight variation evaluation   
The purpose of this test is to assure the uniformity of weight among furosemide ODMTs. 
For that, twenty tablets from the formulated batch were selected randomly and the 
average weight was determined. Then each individual tablet was weighed and 
compared with the average weight of tablet to calculate the standard deviation. 
Standard deviation for each tablet weight was calculated using the following formula: 
Random tablet weight X 100/average tab weight 
Tablet dimensions 
Thickness determination is usually applied to evaluate the influence of thickness on 
disintegration time and the uniformity in thickness amongst the same batch tablets. For 
that, five random tablets from the batch were picked and measured for thickness 
determination using Mitutoyo Digimatic Caliper (CD-12”C) and the measures obtained 
were recorded. 
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Hardness measurement 
Tablets must be able to withstand the rigors of handling and transportation experienced 
in the manufacturing environment, in the drug distribution system and tablet handling 
by the consumer. Ideally, orally disintegrating tablets have a hardness of 20-30 N. 
The hardness test was used to determine crushing strength of furosemide ODMT’s. 
For that, Schleuniger-4M tablet hardness tester was used and 10 tablets were selected 
randomly and their crushing strengths were recorded.  
Friability 
Friability test is applied to measure the tendency of furosemide ODMT to chip, crumble 
or break while handling. This test was determined using Copley Friabilator FR-1000. 
The device subjects the tablets to the combine effect of abrasion and shock in the 
plastic chamber revolving at 25 rounds per minute (RPM) for 4 minutes. For this test, 
ten tableted were selected randomly, weighed and then placed in the friabilator. The 
tablets were collected after 100 rounds (4min), de-dusted using fine sieve and 
reweighed. Using the formula W1-W2 x 100/W1, where: (W1) is the weight of 10 tablets 
before the test and (W2) is the weight of 10 tablets after the test, friability will be 
calculated. According to Ph. Eur., weight loss of not more than 1% is acceptable for 
most tablets. 
In vitro disintegration time 
This test is used to determine the time required for each ODMT to disintegrate into 
small particles when contacting with an aqueous surface (e.g. saliva). Disintegration 
testing was performed by placing a tablet on wet tissue saturated with saliva solution. 
The test was conducted at room temperature and the tablet will pass the test after a 
full disintegration occurs and it becomes small particles.  
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Wetting time 
Wetting time is relative to the inner structure of tablets and the hydrophilicity of the 
excipients used in the formulation. This test was conducted to measure the time 
required for an aqueous phase to penetrate into furosemide ODMT reaching its centre 
and surface. This was performed by placing a tablet gently into direct contact with wet 
tissue in petri dish and the aqueous phase was dyed blue in order to help distinguishing 
once the wetness reaches the tablet surface.  
Uniformity of dispersion  
This test was obtained by placing 3 random tablets of each batch in 25 ml of water and 
a gentle stirring was applied until the 3 tablets were completely dispersed. The 
dispersion was then passed through sieve screen with a nominal mesh aperture of 
1mm (BS410/Endoecotts) to check if full dispersion was achieved. 
Visual characterisation of batches 1-16 
The 16 formulated batches were inspected visually by using high-resolution optical 
zoom camera.  
Disintegration step analysis 
This process was performed by placing one furosemide ODMT into an aqueous droplet 
and the tablet was filmed during the disintegration process which involved wicking and 
swelling mechanisms then a full dispersion was observed. 
Drug content analysis  
This test was performed to ensure the uniformity of furosemide API content amongst 
all formulated ODMTs. Three tablets were selected at random from each batch and 
dissolved in methanol using 10ml volumetric flask. The mixture was then sonicated for 
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10 minutes and made up to mark with the addition of deionized water to form 100µg/ 
ml concentration. A stock solution of furosemide pure standard powder was prepared 
at (1mg/ml) with methanol to obtain serial dilutions. Six serial dilutions (aliquots) were 
prepared from stock solution and diluted in deionised water ranging from 25 to 150 
µg/ml. Once calibration curve obtained, the ODMTs sample were injected and their 
areas were collected in order to quantify the content of furosemide in each tablets. 
Quality Control test of Furosemide Oro-dispersible Mini tablets 
For that, the dissolution test was conducted if tablets were swallowed instead of being 
dispersed on tongue. Dissolution test is the process by which the molecules transform 
from solid phase state and enter into solution state. This test was performed to analyse 
by quantifying the proportion of furosemide drug released from furosemide ODMT into 
a simulated gastric fluid under controlled conditions such as temperature and 
simulated gastric motility (mixing by paddle). Dissolution test was performed using a 
Hanson Research SR8-Plus Dissolution Test Station, which consisted of paddle with 
1-litre glasses. The dissolution medium was 900ml of aqueous solution (pH4) and no 
dissolution accelerating components were added. The dissolution experiments were 
conducted at 37ºC ±0.5 ºC at a paddle rate of 50 rpm for 15 minutes.  At pre-determined 
intervals 5ml of gastric medium was sampled at 5, 10 and 15 minutes filtered and 
injected for analysis using HPLC (20µl).   
2.4.7 Analysis of the design of experiments 
Using the Design Expert™ software (Stat-Ease Inc., Minneapolis, USA), the main interaction 
effects of the four factors on the seven response levels (e.g. tablet hardness, friability etc.) 
were determined by analysing the experiments design. 
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2.4.8 Furosemide ODMT stability testing 
This test was conducted to evaluate the stability, impurity and assay of furosemide ODMTs 
under ICH conditions (humidity, temperature and light). The stability study was conducted on 
one batch only (Batch 15) since all batches contained same ingredients. However, before the 
stability test was performed the furosemide ODMT’s were packaged in a container closure 
system that is very similar to the blister packaging proposed for storage and distribution. 
Furosemide ODMTs were packaged using blister packing and each package box contained 
two tablets of furosemide ODMT’s where the packaging was composed of transparent plastic 
body sealed with an adhesive laminated paper as displayed in figure 18. 
Figure 18: Furosemide ODMT Packaging 
 
The stability testing was performed according to ICH conditions so called accelerated stability 
testing principle at 50ºC ±2ºC temperature and 75±5% relative humidity using an incubator 
(Sanyo MLR-351H). 
A packaged batch of furosemide ODMTs was left in incubator for 12 weeks then analysed for 
any degradation using RP-HPLC.  
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Chapter 3 
3.1 Morphological Analysis Results 
Based on the cross-consistency assessment, the reduced problem space consists of 17,788 
feasible options taking into account of only the logical constraints, which means a reduction of 
85% of the problem space was achieved as seen in Figure 19. 
Figure 19: Solution Space showing feasible options listed in the left hand column 
 
From Figure 19, it is seen that for newborn babies, there are 2288 options, including oral 
solution; suspension, emulsion and injectable dosage form that can be used (taking into 
account clinical indications, contraindications, practice considerations as assessed by the 
CCA matrix). Oral liquids (unlike solid dosage forms such as tablets and capsules) do give 
concerns to palatability as constituents of the formula can diffuse easily to taste receptors. For 
 81 
injectable, palatability is clearly not a concern as this dosage form is not given orally. The blue 
shaded cells represent what is compatible with the red input cell. Thus, certain excipients 
should ideally not be used in newborns such as ethanol or propylene glycol (CNS depressants), 
propyl or butyl hydroxybenzoates as preservatives (oestrogenic effects) and sodium benzoate 
or benzoic acid and benzyl alcohol also as preservatives (now contraindicated according to 
the EMA). 107 
Figure 20: Display field showing output (solutions) in blue for given input condition in red 
 
By using this interactive and dynamic decision support matrix, the numbers of options that are 
possible for each paediatric age group and pharmaceutical dosage form are shown in Table 
16. 
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Table 16: Potential oral dosage forms for different paediatric age groups as informed by 
morphological analysis 
Pharmaceutical dosage form 
Paediatric 
age group 
Solution Suspension Emulsion Tablet 
or 
capsule 
Chewable or 
orodispersible 
Flexible 
dosage 
forms 
Injectable 
Neonates 774 774 540 0 0 0 200 
Infants 904 1058 670 0 0 0 200 
Young 
children 
1240 1442 826 312 624 468 240 
Older 
children 
813 1080 477 312 468 468 140 
Adolescents 813 1080 477 312 468 468 140 
The greatest need for age-appropriate dosage form for furosemide is for neonates, infants and 
young children. Using MA, this decision support tool suggests that that a suspension could 
cover all three age groups taking into account the uncertainties, as assessed in the CCA matrix. 
However it was decided to concentrate the development on the following two dosage forms: 
 Emulsion: furosemide is a poorly-water soluble drug that can be made as a suspension. 
However nasogastric tube administration, often needed in neonates with LCOS, can be a 
problem due to blockage from suspension particulates and complex viscosity patterns of 
suspensions through narrow-bore tubes. In regards to solution, it’s known not to form any 
risk on nasogastric tube. However, solutions do not enhance solubility unless a solvent 
such as ethanol is added which is banned for infant. Emulsion instead can enhance the 
solubility of poor water-soluble molecule such as furosemide if surfactants are used and 
some of these surfactants are safe to use in infants. In addition, there is a paucity of 
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current research in the science of emulsion dosage form design despite the development 
of novel emulsifiers. As such, this gave an opportunity to explore this avenue of research. 
 Oro-dispersible mini-tablets (ODMT): these are flexible dosage forms in that 2 - 4 mm 
tablets can be made incorporating lower doses of furosemide (or any other APIs). 
Contemporary research108  indicates that young children are able to use ODMT thus 
affording dose titration and achieving the correct maintenance dose without resorting to 
breaking large adult strength tablets. By using acceptable excipients such as mannitol, 
these mini-tablets can afford rapid disintegration in the mouth, further minimising 
problems of choking. For parents and caregivers, there is the additional advantages of 
portability and spitting difficulty compared to emulsions and better long-term stability. 
Therefore ODMTs were selected as a second solution space to be investigated practically 
for viability.  
3.2 Discussion 
According to previous published literature, neither MA nor any other forms of PSMs have been 
used in drug development or developing pharmaceutical formulations, let alone in the design 
of paediatric medicines. However, there have been few applications of PSMs in improving 
healthcare services such as the development of modelling method selection tool for health 
services management109, agreeing a local paediatric care strategy110.  Nevertheless, Parallel 
Coordinate Geometry (PCG), which shares some similarities in principle with MA, has been 
employed in in the design of pharmaceutical formulations. PCG is a graphical methodology 
that enables multidimensional data to be displayed in two dimensions. There is a paucity of 
research published in literature using PCG with the principal paper entitled ‘Graphical 
representation of formulation data for analysis and optimisation’111  being one of the few 
articles describing the process in any great detail.  The critical difference of PCG compared to 
MA is that the former uses quantifiable data whereas the latter is capable of incorporating 
qualitative (i.e. descriptive) data. Additionally, PCG creates a factorial design and performs it 
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prescriptively. However, MA is a prospective method in that it creates a theoretical framework 
by analysing the problem and synthesising via the CCA process to yield a solution space for 
experimental testing.  
MA by offering the ability to cover any number of dimensions (variables) of a complex problem 
and by allowing the inclusion of qualitative and quantitative data created the most optimal 
decisions, resulting in the selection of a microemulsion and an orodispersible mini-tablet 
dosage form (ODMT). Unfortunately, with MA some limitations were encountered. For 
example, each subject matter specialist had to be consulted individually rather than the 
preferred group format approach. This was principally due to the fact that a number of 
workshops session are needed (3-4 days), making it difficult to convene such specialists.  The 
only way to collect and assess data was by interviewing each stakeholder individually and this 
posed a limitation on the scope of action and influenced the synthetic phase of MA including 
i.e. CCA. It is hoped that future work can explore the use of technology like real-time decision 
conferencing to elicit a group-based problems structuring approach. 
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Chapter 4 
4. Furosemide Microemulsion Formulation Results  
4.1 Acceptable Daily Intake Values for Microemulsion Excipients 
4.1.1 Transcutol-HP 
The average weight for paediatric age groups varies and so does the ADI value. Therefore, 
the ADI was calculated for Transcutol-HP and other excipients after evaluating the maximum 
daily dose of furosemide for each age group and their average weight as shown in Table 17.  
Table 17: Calculated dose for Transcutol-HP in different age groups 
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1m 3.5 12mg/kg 42 42 4.2 35 0.84 
3m 6.1 12mg/kg 73.2 73.2 7.32 61 1.464 
6m 7.6 12mg/kg 91.2 80 8 76 1.6 
1y 9 12mg/kg 108 80 8 90 1.6 
3y 14 12mg/kg 168 80 8 140 1.6 
5y 18 12mg/kg 216 80 8 180 1.6 
7y 23 12mg/kg 276 80 8 230 1.6 
10y 32 12mg/kg 384 80 8 320 1.6 
12y 39 12mg/kg 468 80 8 390 1.6 
14y 49 120mg 120 120 12 490 2.4 
18y F 58 120mg 120 120 12 580 2.4 
18y 
M 
68 120mg 120 120 12 680 2.4 
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It can be concluded that the maximum dose administered of furosemide microemulsion gives 
2.4mg of Transcutol-HP/ day which is below the ADI (10mg/kg/day). Thus, the safe 
administration of Transcutol-HP and its maximum dose falls within the ADI acceptable values. 
4.1.2 Labrasol 
Labrasol can be administered safely to humans by oral route at dose levels up to 1800mg/ 
day. Based on that, the labrasol limits of administration were calculated, shown in Table 18. 
Table 18: Calculated dose for labrasol in different age groups 
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1m 3.5 12mg/kg 42 42 4.2 105 2.52 
3m 6.1 12mg/kg 73.2 73.2 7.32 183 4.392 
6m 7.6 12mg/kg 91.2 80 8 228 4.8 
1y 9 12mg/kg 108 80 8 270 4.8 
3y 14 12mg/kg 168 80 8 420 4.8 
5y 18 12mg/kg 216 80 8 540 4.8 
7y 23 12mg/kg 276 80 8 690 4.8 
10y 32 12mg/kg 384 80 8 960 4.8 
12y 39 12mg/kg 468 80 8 1170 4.8 
14y 49 120mg 120 120 12 1470 7.2 
18y 
F 
58 120mg 120 120 12 1740 7.2 
18y F 68 120mg 120 120 12 2040 7.2 
By comparing the date obtained from ADI which indicates the Labrasol limits/kg/day to the 
maximum Labrasol administered from the formulated furosemide microemulsion, it can be 
clearly observed that the maximum amount of Labrasol administered falls within the safe limits 
of the acceptable daily intake values and hence forms no harm being used in furosemide 
microemulsion formulation. 
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4.1.3 Labrafac (Medium Chain Triglycerides) 
Labrafac has no toxicological effects reported and is considered safe. Furthermore, it can be 
administered safely to humans. Thus, the amount of Labrafac used in doses of furosemide 
microemulsion is calculated as shown in Table 19. 
Table 19: Calculated dose for Labrafac in different age groups 
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1m 3.5 12mg/kg 42 42 4.2 Not Limited 0.588 
3m 6.1 12mg/kg 73.2 73.2 7.32 Not Limited 1.0248 
6m 7.6 12mg/kg 91.2 80 8 Not Limited 1.12 
1y 9 12mg/kg 108 80 8 Not Limited 1.12 
3y 14 12mg/kg 168 80 8 Not Limited 1.12 
5y 18 12mg/kg 216 80 8 Not Limited 1.12 
7y 23 12mg/kg 276 80 8 Not Limited 1.12 
10y 32 12mg/kg 384 80 8 Not Limited 1.12 
12y 39 12mg/kg 468 80 8 Not Limited 1.12 
14y 49 120mg 120 120 12 Not Limited 1.68 
18y (F) 58 120mg 120 120 12 Not Limited 1.68 
18y 
(M) 
68 120mg 120 120 12 Not Limited 1.68 
To conclude, all furosemide microemulsion excipients used in the proposed formulation were 
within their respective ADI limits. This assures the administration’s safety aspect of the 
furosemide microemulsion and justifies its formulation and development. 
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4.2 HPLC Method development Results 
The method developed consisted of the mobile phase of H3PO4 (0.5% aqueous) with pH 3.2 
and methanol under gradient conditions. Under these conditions a clear peak was observed 
with elution time achieved at 11.71 minutes.  
4.2.1 HPLC Injections Results 
After injecting the serial dilutions standards, chromatograms were obtained and the data 
(areas) were collected. Once the calibration was achieved, diluted labrasol and labrafil filtrates 
were injected separately and their chromatograms were obtained. Figure 21 represents a 
typical chromatogram obtained from standard furosemide sample injected into HPLC. 
Figure 21: The typical chromatogram representing the standard furosemide 
 
4.2.2 Linearity Results 
Serial concentrations of furosemide API were used to measure the linearity plot and areas 
were recorded as shown in Table 20. 
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Table 20: Areas recorded for aliquots using HPLC 
Concentration Area 
1 50 µg/ml 110.941 
2 100 µg/ml 223.306 
3 150 µg/ml 331.856 
4 200 µg/ml 443.686 
5 250 µg/ml 557.229 
6 300 µg/ml 665.52 
The plot of peak areas responses against concentrations of furosemide created the calibration 
curve with excellent linearity (figure 22). 
Figure 22: Linearity plot for furosemide drug substance 
 
4.2.3 Concentration calculation of furosemide in the surfactants 
 Area of furosemide in Labrasol surfactant was 4998.827 units 
Concentration found = 45.02 mg/ml 
y = 111.04x + 0.1069
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 Area of furosemide in Labrafil surfactant was 371.5 units 
Concentration found = 3.34 mg/ml 
4.2.4 Solubility study 
According to the data obtained from analysing both surfactants and quantifying the amount of 
dissolved furosemide using HPLC, furosemide showed far higher solubility rate in labrasol 
surfactant than labrafil (Figure 23). Hence labrasol was selected to formulate the 
microemulsion. 
Figure 23: The solubility of furosemide in Labrasol and Labrafil Surfactants 
                            
4.2.5 Phase diagram construction of Furosemide microemulsion 
A series of microemulsions were formed, prepared and their self-emulsifying properties were 
observed visually as shown in Figures 24, 25 and 26. 
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Figure 24: Pseudo-ternary phase diagram indicating the efficient self-emulsification region at 
[S/Co-S= 1:1(v/v)] 
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Figure 25: Pseudo-ternary phase diagram indicating the efficient self-emulsification region at 
[S/Co-S= 2:1(v/v)] 
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Figure 26: Pseudo-ternary phase diagram indicating the efficient self-emulsification region at 
[S/Co-S= 3:1(v/v)] 
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It was observed that the efficiency of emulsification improved when the proportion of Labrasol: 
Transcutol-HP S/Co-S concentration contained at least 30% of the total composition. In 
addition, it was noticed that increasing the concentration of Transcutol-HP co-surfactant in the 
composition increased the spontaneity of self-emulsification region. Therefore, the higher 
concentration of Transcutol-HP co-surfactant S/Co-S= 1:1(v/v), the larger is the self-
emulsifying region in phase diagrams (Figure 24). However, the stability of the self-emulsifying 
formulations with the ratios of S/Co-S= 2:1 and S/Co-S= 1:1 was decreased because of a 
slight precipitation observed visually after 24 hours. This could be due to the dilution of labrasol 
surfactant which showed an optimum solubilising ability to furosemide API. Meaning, the 
higher the labrasol concentration, the greater is the solubility and hence is the stability. Thus, 
the ratio of Labrasol:Transcutol-HP S/Co-S 3:1 was chosen for the composition of furosemide 
microemulsion as shown by the red arrow  in Figure 26. 
4.2.6 Furosemide Microemulsions Compositions 
The series of furosemide microemulsion formulations obtained were prepared as shown in 
Table 21 and each concentration ratio was given a formulation code (FC). 
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Table 21: Composition of furosemide microemulsions 
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FC 1 5% 5% 90% 10mg/ ml Transparent Stable 
FC 2 14% 6% 80% 10mg/ ml Transparent Stable 
FC 3 25% 5% 70% 10mg/ ml Transparent Stable 
FC 4 36% 4% 60% 10mg/ ml Transparent Stable 
FC 5 47% 3% 50% 10mg/ ml Transparent Stable 
FC 6 58% 2% 40% 10mg/ ml Transparent Stable 
FC 7 69% 1% 30% 10mg/ ml Transparent Stable 
Although, all above formulations showed good physical stability, the second formulation (FC 
2) was chosen, containing MCT Oil 14%, Labrasol 60%, Transcutol-HP 20% and Water 6% 
for further testing. 
 Characterisation and Evaluation of Furosemide Microemulsion 
4.2.7 Drug content analysis using RP-HPLC 
The drug content in furosemide microemulsion sample (60µl) was found to be 597.8µg. The 
percentage of furosemide drug content was calculated to be 99.6%, which is considered 
acceptable according to Drug Content Acceptance Value (DCAV) of the British Pharmacopeia 
(BP)112. A typical chromatogram is shown in Figure 27 representing an injected furosemide 
microemulsion sample. 
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Figure 27: Chromatogram of furosemide microemulsion 
 
4.2.8 Phase separation study  
There was no sign of precipitation observed for the whole period of monitoring and the sample 
remained clear and stable throughout the test indicating good phase stability with no sign of 
separation or precipitation.  
4.2.9 Droplet size determination of furosemide microemulsion 
The droplet size measured was found to be 137.4nm with a low polydispersity index (PDI) of 
0.07 as seen the Figure 28. 
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Figure 28: Droplet size determination using dynamic light scattering 
 
 
4.2.10 Viscosity determination of furosemide microemulsion 
The viscosity results are shown in Table 22. 
Table 22: Viscosity determination of furosemide microemulsion 
1) Furosemide microemulsion formulation 
viscosity measurement at 1 minute: 
61.0 cP 
2) Furosemide microemulsion formulation 
viscosity after 30 minutes from first reading: 
61.1 cP 
4.2.11 Dynamic Surface Tension Measurement 
The examinations were performed on the day of preparation and one week after later. Results 
obtained at different times showed same values and the data were recorded. 
Water/ MCT oil surface tension 
The surface tension measured of W/O was 86.3 - 88.3 mN/m as presented in Table 23. 
 98 
Table 23: Water/ MCT oil surface tension reading 
 
Water/ Oil and surfactant surface tension 
The surface tension value of W/O+surfactant dropped as expected and was found to be 30.2 
– 31.0 mN/m as shown in Table 24. 
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Table 24: Water/ Oil and Surfactant surface tension reading 
 
By comparing both surface tension values, Labrasol showed great reduction to surface tension 
of w/o emulsion from 88.27 to 30.21 mN/m which confirmed the important role labrasol plays 
as an interfacial surface tension reducer. This is expected to enhance the stability of the 
microemulsion preventing phase separation. 
4.2.12 Furosemide microemulsion conductivity measurements 
The conductivity of furosemide microemulsion was found with 0.53μS value and stayed the 
same after similar trials which confirmed the stability of microemulsion with no phase inversion 
observed. 
4.2.13 Drug-excipient compatibility studies using FTIR 
The FTIR spectrum of furosemide was obtained from a solid phase state using Agilent FTIR 
spectroscopy as shown in Figure 29.  
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Figure 29: Furosemide standard powder FTIR spectrum 
 
The spectrum obtained in Figure 29 shows well-defined bands with relatively high intensity in 
the 1700-700 cm-1 wavenumber range. A comparison of the furosemide FTIR spectrum versus 
furosemide reference spectrum (Figure 30) from the International Pharmacopeia reference 
showed a similar frequency correlation. 
Figure 30: Furosemide reference spectrum (the international pharmacopeia) 113 
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The chemical sulphur group gives specificity to the furosemide chemical structure. Indeed, 
SO2 and SO sulphur compound groups produced strong IR bands in the 1400-1100cm-1 with 
two main wavelengths at 1141 and 1320 cm-1.  Amine shows stretching band for NH and NH2 
in the range of 3200 and 3400cm-1 with three main peaks at 3398, 3350 and 3283cm-1. The 
C=O peak was observed at 1670cm-1 and the OH band was in the range of 2400-3150cm-1. 
The FTIR spectrum of microemulsion was then collected as shown in Figure 31. 
Figure 31:  FTIR spectrum of furosemide microemulsion 
 
Unfortunately, the obtained microemulsion spectrum did not show the furosemide 
characteristic peaks in order to identify them and hence the furosemide. Placebo 
microemulsion (drug-free formulation) was analysed used FTIR to compare it to furosemide 
microemulsion IR spectrum (Figure 32).  
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Figure 32: Placebo microemulsion FTIR Spectrum 
 
Furosemide peaks could not be identified and had no difference when its IR microemulsion 
spectrum was compared with placebo microemulsion spectrum. In fact, there was an 
appearance of two minor peaks in placebo’s spectrum at 1660 & 1600 cm-1 but they had no 
significance toward furosemide’s identification. Furosemide concentration was quadrupled in 
microemulsion and a sample was analysed using FTIR but again no difference was observed. 
Therefore, it is was concluded that the disappearance of furosemide peaks was caused by the 
overlapping of microemulsion excipients spectral bands over furosemide API bands and led 
to the obscuration of the furosemide API peaks by surfactants and co-surfactants stretching 
bands. This concluded that FTIR could not be used for drug-excipient compatibility and 
stability analysis of furosemide microemulsion and therefore, HPLC and NMR tests were 
applied for this purpose. 
4.2.14 Furosemide Drug-excipients compatibility studies using NMR 
The NMR spectrum of furosemide API was obtained after dissolving it in acetone using Bruker 
NMR as shown in Figure 33. 
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Figure 33: 1H NMR spectrum of Furosemide using acetone solvent 
 
By analysing the proton peaks of furosemide NMR spectrum, the correlated hydrogen atoms 
have been assigned (1-7) as shown in Figure 34. 
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Figure 34: Furosemide structure with numbers of hydrogen types identified 
 
Furosemide microemulsion was then diluted using acetone solvent and analysed using NMR. 
Figure 35 shows diluted furosemide microemulsion spectrum. 
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Figure 35: Furosemide microemulsion spectrum using acetone solvent 
 
By comparing both spectra of pure furosemide standard and furosemide microemulsion, it was 
observed that proton peaks’ places and shifts are identical with no difference. This showed 
that no interaction had been exerted on furosemide molecule following formulation of the 
microemulsion and proved a good compatibility between furosemide and microemulsion’s 
excipients. 
4.2.15 Visualisation of furosemide microemulsion using light microscopy 
It was barely possible to spot the water droplets dispersed into the oily phase at 20X 
magnification where furosemide drug is dissolved as shown in Figure 36. 
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Figure 36: Microscope image of furosemide microemulsion magnified to 20X 
 
The conjugated aqueous droplets were then gradually disintegrated into discrete, seemingly 
spherical droplets. Higher magnifications were applied and figures 37 and 38 are pictures 
captured showing the aqueous content and distribution over the oily phase at 40X and 60X 
respectively. 
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Figure 37: Microscope image of furosemide microemulsion at 40X with excess aqueous 
droplets added to the furosemide microemulsion preparation 
 
Figure 38: Microscope image of furosemide microemulsion at 60X shows disintegrated 
aqueous droplets onto the oily phase of the microemulsion 
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4.2.16 Temperature stability studies 
Furosemide microemulsion was found to be stable in the freeze-thaw cycle and there were no 
signs of phase separation or precipitation observed. The results obtained were summarized 
in Table 25. 
Table 25: Thermodynamic stability results 
Thermodynamic stability and precipitation studies for furosemide 
microemulsion 
Centrifugation 
test 
Freeze 
thaw 
cycle 
Precipitation after 1-6 hours 
1 h 2 h 3 h 4 h 5 h 6 h 
No phase 
separation 
No phase 
separation 
Clear Clear Clear Clear Clear Clear 
4.2.17 Palatability testing 
Unfortunately, the palatability tests were not successful because the sample damaged the 
sensors of E-tongue. The E-tongue manufacturers were contacted and the company stated 
that C00 sensors could be damaged if exposed to surfactants e.g. labrasol as they get 
adsorbed onto the sensors surface, which in fact, caused the damage to sensors. 
4.2.18 Shelf Life Studies 
Stability studies under stress temperature conditions 
The output of injected furosemide microemulsion showed chromatogram with a clear peak as 
shown in Figure 39. 
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Figure 39: Furosemide microemulsion chromatogram 
 
The furosemide microemulsion areas were recorded at 2381, 2379 and 2383 from 30, 40 and 
50°C samples respectively. Using the calibration equation, the concentration of microemulsion 
samples were calculated and the values were summarised Table 26. 
Table 26: Concentrations obtained at different temperatures 
Sample record Area Concentration 
Sample 1 at 30 °C 2381 50.18 µg/ ml 
Sample 2 at 40 °C 2379 50.13 µg/ ml 
Sample 3 at 50 °C 2383 50.22 µg/ ml 
By comparing the results obtained with the expected concentration of injected microemulsion 
samples (50µg/ml), it can be observed that the samples concentrations remained the same 
under stress conditions. Moreover, the results indicated a good stability of furosemide in the 
microemulsion dosage form at these conditions over 60 days as no degradation of the API 
was observed. 
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Long term stability studies 
The concentration obtained was 50.4µg/ml with clear sharp peak indicating great stability as 
shown in Figure 40. 
Figure 40: Furosemide microemulsion chromatogram recorded after 12 months shelf life 
storage 
 
 
4.2.19 Long term phase separation study 
After 12 months of preparation, there was no sign of precipitation observed during the 6 hours 
monitoring and sample remained clear throughout the test indicating good phase stability with 
no sign of separation or furosemide precipitation. 
4.2.20 Long term viscosity determination of furosemide microemulsion 
After 12 months of preparation, the measured viscosity remained similar to the initial viscosity 
measured at time of preparation as presented in Table 27. 
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Table 27: Viscosity determination of furosemide microemulsion 
1) Furosemide microemulsion formulation 
viscosity measurement at 1 minute: 
62.0 cP 
2) Furosemide microemulsion formulation 
viscosity after 30 minutes from first reading: 
59.0 cP 
4.2.21 Discussion 
Furosemide is considered as an age-appropriate oral dosage form, preferred for neonates, 
infants and young children. The fact that microemulsion as a dosage form is almost absent on 
the commercial market, has good solubilising property compared to other dosage forms for 
poorly water soluble molecules and the novel application of surfactants, such as Labrasol, 
Transcutol-HP and Labrafac has contributed to new knowledge to the field of paediatric 
formulation design. 
According to the published literature, no microemulsion has been manufactured incorporating 
furosemide. The majority of microemulsions that have been formulated were designed for 
transdermal routes (e.g. tretinoin 114 , aceclofenac 115  and nimodipine 116 ) and for nasal 
administration (carbamazepine117). However, there are a few reports that detail the oral route 
for molecules such as biphenyl dimethyl dicarboxylate (BDD) for the treatment of liver disease 
and clinidipine for hypertension118.  
The published article on clinidipine (BCS class II) microemulsion stated that it has droplet size 
(globule) of 13.3nm119. However, furosemide microemulsion in this research had droplet size 
of 137.4nm. According to microemulsion field, droplet size can range between 20-200nm, so 
it is unclear if clinidipine in fact was swollen micelle. With reference to the Handbook of 
Microemulsions science and technology120, droplet size depends on interfacial tension and 
entropy of mixing. The variation in droplet size is also a function of concentration, which means 
larger amounts incorporated in microemulsion will yield larger droplet size. Chemically, 
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furosemide’s partition coefficient log P value is 3 with pKa value of 3.9. Itraconazole 
microemulsion with a log P of 5.7 and pKa value of 3.7 exhibits a droplet size of 150nm121 
while glimepiride microemulsion (log P 3.5 and pKa 3.7) gave a value of 176.1nm122. Thus, it 
would appear that the variation in the physico-chemical properties of the drug results in the 
differing sizes, not to mention the type and level of surfactant(s) used. Table 28 summarises 
the pertinent details of microemulsions as reported in the literature. It is difficult to ascertain 
the relationship between droplet sizes with the varying parameters such as HLB value and 
water level. 
Table 28: Examples of oral microemulsion reporting the excipient type and level used 
Microemulsion Oil Surfactant Co-surfactant 
Water 
level 
Drug 
Ratio 
Droplet 
size 
Atorvastatin123 
(W/O) 
Log P: 5.7 
pKa: 4.3 
Castor oil 
13% 
Labrafil 
61% 
HLB: 4 
Transcutol-HP 
HLB: 4.2 
20% 
6% 10mg/ml 28.27nm 
Itraconazole 
(O/W) 
Log P: 5.7 
pKa 3.7 
Oleic acid 
 
Tween 80 
HLB: 15 
Ethanol 
HLB: 4.2 
Unknown Unknown 150nm 
Glimepride  
(O/W) 
Log p: 3.5 
pKa 3.7 
Cremphor
e RH 40 
(32%) 
Labrafil 
HLB: 4 
8% 
Transcutol-P 
HLB: 4 
8% 
52% 20mg/ml 176.1nm 
Clinidipine  
(O/W) 
Log p: 5.42 
pKa 2.61 
Tocotrienol 
Tween 20 
HLB: 16.7 
Transcutol-HP 
HLB: 4.2 
Unknown Unknown 13nm 
Furosemide 
(W/O) 
Log P: 3 
pKa: 3.9 
MCT 
14% 
Labrasol 
HLB: 14 
60% 
Transcutol-HP 
HLB: 4.2 
20% 
4% 10mg/ml 137.4nm 
In terms of drug-excipient compatibility studies, majority of published papers on 
microemulsions prioritised physical stability studies and did not conduct compatibility 
assessments. However, few articles such as simvastatin124 and telmesart125 microemulsions 
investigated the excipient compatibility using FTIR. Unfortunately, using FTIR for furosemide-
excipient compatibility was not successful because furosemide bands were obscured by 
excipient absorption. Proton NMR, however, appeared to indicate good excipient compatibility 
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as proton peaks places and shifts were identical between reference furosemide and 
furosemide microemulsion. In reviewing previous literature on microemulsions this type of 
analysis has not been performed before and the only published source citing NMR explored 
the characterisation of vinpocetine microemulsion for transdermal delivery to assess the 
correlation between the transdermal permeation rate and structural characteristics of 
vinpocetine.126 
It is also worth noting that majority of research conducted on microemulsion focused on the 
method of formulation without indicating the intended patient population. Therefore, no toxicity 
studies or data on microemulsion excipients were mentioned. Additionally, no attention was 
given to paediatric patients except for a single source from Wisch (2000) that reported a 
microemulsion for the treatment of paediatric patients with tuberculosis127. Again no toxicity 
values or studies were given in the thesis and only the age-appropriateness of the 
microemulsion as a dosage form was discussed as the main concern. In this research by 
contrast, excipient toxicity concerns and ADI values were assessed for all paediatric age 
groups based on body weight and therapeutic doses to give a patient-centric approach. 
A major concern with liquid dosage forms is palatability and taste masking. Unfortunately, no 
studies were conducted on palatability for furosemide microemulsion as in vivo testing had 
ethical constraints and in vitro testing could not be performed because the surfactants in the 
furosemide microemulsion damaged the E-tongue electrode. However, this is a critical quality 
attribute and it is hoped that alternative methods can be developed in the near future to 
overcome such constraints.   
For the sake of completeness, there is a single published report of a furosemide self 
microemulsifying drug delivery system (SMEDDS).128 However, SMEDDS formulation exhibits 
significant differences to the ready-to-use microemulsion developed in this work. For instance, 
SMEDDS is an oil and surfactant single-phase mixture and only becomes dispersed once it 
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encounters the gastric liquid content (chime) under gentle agitation (motility) of the intestine 
(i.e. a pre-concentrate is formed and administered as the dosage form). In contrast for 
microemulsions, the dispersed phase (water in this research) is dispersed in continuous phase 
(e.g. MCT) and stabilised with surfactant and co-surfactant combination before administration. 
Finally, despite the significant advantages of microemulsions, these dosage forms have some 
drawbacks and limitations. For example: 
 Microemulsions require large concentration of surfactant and co-surfactant to form 
stabilisation129.   
 Many of surfactants and co-surfactants are new on to the market and not widely used, 
therefore there is no long-term clinical safety data.  
 Small number of pharmaceutically acceptable excipients (classified as generally regarded 
as safe) are available compared to other dosage forms.130 
 An obstacle is usually met when developing a microemulsion is the lack of good predictive 
in vitro models for palatability assessment of the formulation.131 
 Microemulsion stability is influenced by environmental parameters such as temperature 
and pH value132. These parameters change upon patient handling and home storage, 
which can lead to a stability issue. 
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Chapter 5 
Furosemide Oro-Dispersible Mini Tablets Formulation Results  
5. Preliminary Work Results for Establishing Process Parameters (pre-formulation 
studies) 
5.1 Drug-Excipient Compatibility Studies 
The DSC thermogram of furosemide sample obtained (Figure 41) showed an exothermic peak 
of recrystallization at 223.55°C (18.97min) and endothermic peak with melting point observed 
at 271.48°C. 
Figure 41:  Furosemide Thermogram Using DSC 
 
The ludiflash DSC thermogram obtained showed an endothermic peak only with melting point 
noticed between 0-300°C range observed at 170.43°C as shown in Figure 42. 
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Figure 42: Ludiflash Thermogram Using DSC 
 
Magnesium stearate gave a thermogram showing two endothermic peaks with different 
melting points (106 and 114.9°C). This usually happens when a combination or mixture of two 
or more compounds are scanned together such as magnesium stearate. European 
Pharmacopeia describes magnesium stearate as a mixture of magnesium salts of different 
fatty acids consisting mainly of stearic acid and palmitic acid and in minor proportions of other 
fatty acids133. Figure 43 shows the thermogram of magnesium stearate. 
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Figure 43: Magnesium stearate thermogram using DCS 
 
The DSC thermogram of Furosemide-Ludiflash sample showed an endothermic peak of 
Ludiflash and exothermic peak of furosemide confirming compatibility as a mixture with no 
signs of interaction between both compounds as seen in Figure 44. 
Figure 44: Furosemide-Ludiflash mixture Thermogram Using DCS 
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Magnesium stearate and furosemide mixture sample gave a DSC thermogram showing multi-
endothermic melting peaks of the excipient and a sharp exothermic peak of furosemide 
confirming the compatibility between the two compounds with no observed interaction as 
shown in Figure 45. 
Figure 45: Furosemide-magnesium stearate mixture thermogram using DCS 
 
Overall, furosemide drug showed no significant interaction or any signs of incompatibility with 
Ludiflash and magnesium stearate excipients for the intended ODMT formulation.  
The pre-compression tests results of batch one will be discussed in details whereas the rest 
of the batches will be summarised bearing in mind that identical characterisation steps were 
followed for all batches. 
5.2 Batch One Pre-Compression Tests Results 
 Angle of repose ()  
Figure 46 displays the pile obtained with the height and diameter values. 
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Figure 46: Batch one pile using funnel method 
 
 
Height of pile: 1.6 cm 
Diameter: 2.3 cm; radius= diameter/2= 1.15 cm 
Thus, angle of repose = Tan -1 (0.69) = 34.6  
   Based on flowability index range, the results were found to be good. 
 Compressibility index (Hausner’s ratio) 
The values were obtained for Hausner’s ratio were: 
Bulk density= 54.23/100=0.5423  
Tapped density =54.23/86=0.63 
      Yielding Hausner’s ratio value of =0.63/0.5423 = 1.16 
     From Table 15, it is seen that the blend exhibits a good flow 
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5.3 Post-Compression Evaluation and Characterisation Results 
This involved a variety of tests. Each test’s results are described separately. 
Weight variation evaluation   
The average weight per tablet was found to be = 27.37mg  
Standard deviation for each tablet weight was calculated as shown in Table 29. 
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Table 29: Individual tablet weight of batch one and their SD to average  
Tablet Weight SD 
1 27.1 99.01% 
2 28.1 102.6% 
3 27.9 101.9 
4 27.2 99.37 
5 27.3 99.7% 
6 27.3 99.7% 
7 27.28 99.6 
8 27.27 99.63 
9 27.67 101% 
10 27.13 101% 
11 27.09 98.9% 
12 27.23 99.48% 
13 27.40 100.1% 
14 27.15 99.19% 
15 27.25 99.56% 
16 27.19 99.3% 
17 27.51 100.5% 
18 27.40 100.1 
19 27.92 102% 
20 27.13 101% 
Tablet dimensions 
The measures obtained for 5 random tablets were recorded in Table 30. 
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Table 30: Shows thickness values of 5 random tablets from batch 1 
Tablet Thickness Diameter 
1 3.15mm 3mm 
2 3.17mm 3mm 
3 3.18mm 3mm 
4 3.15mm 3mm 
5 3.15mm 3mm 
Figure 47 shows the formulated furosemide ODMT size in this research compared to other 
existing tablets on the market of different sizes. 
Figure 47: Furosemide ODMT size compared to other sizes 
 
Hardness measurement 
The hardness of the 10 randomly selected tablets was recorded in Table 31. 
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Table 31: Crushing strength values of 10 tablets from batch 1 
Tablet Crushing Strength (N) 
1 29N 
2 23N 
3 28N 
4 21N 
5 27N 
6 29N 
7 28N 
8 33N 
9 29N 
10 21N 
 
Friability 
 The friability for batch one was found 0.3%.  According to Ph. Eur., weight loss of not 
more than 1% is acceptable for most tablets and thus the friability of batch one (<1%) was 
considered acceptable. 
In vitro disintegration time 
Disintegration time for batch 1 ODMT was found to be 19 seconds. 
Wetting time 
The wetting time for this batch (1) was found to be 16 seconds. Figure 48 was captured 
when wetting was observed at one of the tablets surface compared to other tablet 
placed later. 
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Figure 48: Wetting test of furosemide ODMT from batch 1 
 
Uniformity of dispersion  
It was observed that there was no retention of any particles or residues on sieve 
surface and the results complied with uniformity of dispersion expectation.   
Visual characterisation of batches 1-16 
Three main types were visually observed as the following: 
Type 1: This type of visualisation was noticed with batches compressed at low compression 
force. It can be seen that the tablet surface was rough and the thickness was higher with 
capillaries, abrasion and large pores on the tablet body (Figure 49).  
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Figure 49: Type one furosemide ODMT’s inspected visually 
 
Type 2: This type was observed at high compression force and mainly at low concentration of 
API and lubricant. It was characterised with a smooth surface, lower thickness than type one 
and shiny non-porous body surface (Figure 50). 
Figure 50: Type 2 furosemide ODMT’s inspected visually 
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Type 3: This particular type was observed at high compression force where lubricant and 
furosemide were used at their maximum concentration 3mg and 0.6% respectively. The tablets 
were characterised by very smooth surface but with clear chipping, cracks and crumples were 
observed in some tablets (Figure 51). 
Figure 51: Type 3 furosemide ODMTs inspected visually 
 
Disintegration step analysis 
The disintegration processes, which involved wicking and swelling mechanisms then 
a full dispersion, were captured as shown in Figure 52. 
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Figure 52: Dispersion process of furosemide ODMT 
 
Drug content analysis  
Using the previously developed HPLC method, an assay values between 103.2 and 
107.1µg/ml were obtained. 
Quality control test results of furosemide ODMTS in dissolution test 
Although the standard furosemide concentration of Batch 1 ODMT in simulated gastric 
juice was expected to be 1.11µg\ml, it was noticed that the samples contained a slightly 
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higher concentrations than expected as shown in Table 32. This is explained as drug 
content had up to 8% extra in some tablets analysed for content from batch 1. 
Table 32: Dissolution samples concentrations at different times 
Dissolution test of Furosemide Oro-dispersible Mini Tablets 
           Time       Concentration (pH4) 
At 5   minutes 1.15 µg (103.6%) 
At 10 minutes 1.19 µg (107.2%) 
At 15 minutes 1.19 µg (107.2%) 
 
Overall, the dissolution rate showed acceptable results and the cumulative release of 
furosemide not only reached standard acceptable range (90-100%) but exceeded it after the 
first 5 minutes of dissolution and only a slight increase was observed over the 2nd and 3rd 
intervals samplings which indicated an excellent dissolution rate within short period of time.  
5.4 Tests Results of Batches 1-16 
The tests results of pre and post-compression batches 2-16 were conducted and evaluated 
as described in the preceding tests. The combined results are shown in Tables 33 and 34. 
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Table 33: Pre-compression parameters for 1-16 batches 
Formulation 
batch 
Angle of repose Hausner’s ratio 
Value Level Value Level 
B1 34.6 Good 1.16 Good 
B2 40.59 Fair 1.14 Good 
B3 29.6 Excellent 1.17 Good 
B4 34.6 Good 1.17 Good 
B5 39.35 Fair 1.16 Good 
B6 40.82 Fair 1.14 Good 
B7 29.6 Excellent 1.17 Good 
B8 32.21 Good 1.17 Good 
B9 34.6 Good 1.16 Good 
B10 40.59 Fair 1.14 Good 
B11 34.6 Good 1.17 Good 
B12 34.99 Good 1.17 Good 
B13 40.8 Fair 1.13 Good 
B14 39.69 Fair 1.14 Good 
B15 35.75 Good 1.17 Good 
B16 34.63 Good 1.17 Good 
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Pre-compression studies and assessments concluded good acceptability for the compression of 
all batches and therefore all batched were formulated using single punch Manesty F3 tablet 
machine with 3mm die diameter. 
Table 34 shows results of compressed batches 2-16. 
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Table 34: Post-compression parameters for 1-16 batches (X refers to batches failed indicated 
tests) 
Post-compression tests results showed unacceptable values for some batches. These values 
were noticed with friability and weight variation tests and the batches which failed the tests were 
Batch 
no. 
Hardness 
Average 
(N) 
Friability 
(%) 
Weight variation Disintegrat
ion Time 
(Sec) 
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e
ttin
g
 tim
e
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e
c
) 
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e
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te
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a
x
 (%
) 
M
in
 (%
) 
Value Acceptance  
(<1%) 
B1 27 0.29 ✔ 27.37 +2.6 -1 19 16 ✔ 
B2 2.2 41.79 X 21.46 +12.11 -21.63 13 13 X 
B3 11.6 3.78 X 22.04 +4.99 -3.68 21 16 X 
B4 5.8 26.51 X 21.35 +9.83 -11.5 29 21 X 
B5 25.7 0.14 ✔ 27.2 +2.13 -2.8 16 11 ✔ 
B6 8.4 5.2 X 25.84 +6.07 -7.36 18 13 X 
B7 12.2 1.34 X 21.85 +4.25 -4.44 23 15 X 
B8 3.4 26.98 X 21.43 +7.6 -9.44 27 21 X 
B9 36 0.721 ✔ 23.42 +14.51 -8.25 34 31 X 
B10 14.3 19.66 X 21.72 +7.96 -9.21 21 19 X 
B11 23.3 0.82 ✔ 24.37 +2.74 -2.84 24 21 ✔ 
B12 10.7 1.16 X 19.97 +5.7 -3.96 37 30 X 
B13 41.6 0.69 ✔ 23.1 +6.27 -8.88 28 26 X 
B14 23.1 1.85 X 22.47 +11.08 -16.11 28 17 X 
B15 24.7 0.73 ✔ 24.45 +2.53 -2.05 27 20 ✔ 
B16 11.7 1.08 X 19.12 +5.4 -2.74 38 29 X 
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excluded from further assessments and analysis.  The batches that showed acceptable values 
were batches 1,5,11 and 15. Hence, they were selected for further studies and evaluation such 
as content uniformity, dissolution and stability tests (section 5.6). 
5.5 Analysis of the Design of Experiments 
Effect on tablet hardness response 
Figure 53: Shows the factors effect on response levels 
 
 
 Increasing the furosemide level from 1 to 3mg on average reduced the hardness by 
15N 
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 Increasing the compression strength from 18 to 19 units increased the hardness by 
~12N 
 Increasing the lubricant level of magnesium stearate from 0.3 to 0.6% reduced the 
strength by 10N 
Intuitively the above makes sense. Increasing furosemide load level within the small confines 
of a mint-tablet is likely to be detrimental, requiring either a higher compaction force or another 
diluent such as microcrystalline cellulose. The latter diluent cannot be used for ODMT as it 
does not render tablets dispersible. It is well known that increasing lubricant levels can lead to 
softer tablets and this has been borne out in these results. There is also a significant interaction 
between the furosemide level and lubricant amount, which reduces hardness by ~ 7N.  
Figure 54 below lists the actual values of the main effects due to furosemide, compression 
and lubricant factors plus the aforementioned interaction effect. 
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Figure 54: shows the list of the actual values with main effects on furosemide ODMTs 
 
 Effect on friability 
Using similar types of graphical analysis and calculations it was observed that surprisingly, 
increasing furosemide level reduced the level of friability by 15% whereas an increase in the 
mixing time and compression force reduced hardness by 7 and 10%, respectively. This is 
counterintuitive. A deeper analysis of the interactions revealed that in fact friability was 
increased 9% given the combination of furosemide and compression factors. This suggests 
that increasing compaction force may in fact push waken ODMT as furosemide is pushed 
towards the periphery or the surface. 
Effect on average tablet weight 
No major effects were observed. 
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Effect on disintegration time 
The only factors of note, as expected, were that increasing compaction force and/or lubricant 
levels increased average increased disintegration time by 9s and 7s, respectively.  
Interestingly, however, there was little interaction between these two factors despite the fact 
that the hydrophobic magnesium stearate will repel water from the tablet surface. 
Effect on wetting times 
The major effect observed was the compression force, which going from 18 to 19 units on the 
Manesty F3 machine settings lead to an average increase of 8s (i.e. reduction in surface 
porosity, or water channels). 
Effect of lubricant levels on powder flowability 
Two response factors were used here: angle of repose and the Hauser ratio. The only affect 
observed of note was, as expected, was the increasing level of the lubricant, which on average 
increased the angle of repose by 5.6°. Lubricants are known to have poor glidant properties.  
No significant effects were seen for Hausner’s ratio simply because of its insensitivity to 
measurement cf. angle of repose response 
Overall, these findings led to the selection of batches 1,3,5 and 11 for further characterisation.  
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5.6 Acceptable Batches (1, 5, 11, 15) Quantitative, Qualitative and Stability Tests Results 
The drug content and dissolution rate results for the acceptable batches is concluded in table 
35. 
Table 35: Dissolution test results of accepted batches 
 
5.7 Furosemide ODMT Stability Testing 
The chromatogram for furosemide ODMT showed a clear peak (Figure 55) and no significant 
impurities or major peaks were detected. 
 
 
 
 
 
 
 
 
 
Batch Number 
 
Drug Content (%) 
Dissolution rate (%) at: 
5 Min 10 Min 15 Min 
B1 3% +8% 103% 107% 107% 
B5 0 +3% 101% 102% 102% 
B11 -2% +3% 99% 101% 103% 
B15 -2% +2% 101% 101% 101% 
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Figure 55: Batch 15 HPLC chromatogram under incubating conditions 
 
The assay content was found 97µg, which is close value with the expected content 
concentration of ODMT (100µcg/ml). This concludes a very slight degradation to furosemide 
drug molecules that may have occurred as tiny impurity peaks appeared between 1.5-2.5 
minutes of chromatogram. 
5.8 Discussion 
MA suggested orally dispersible mini-tablets (ODMTs) as a flexible solid dosage form which 
is considered as age-appropriate for infants and children.  ODMTs are a valuable alternative 
to liquid dosage forms in terms of good solid-state stability and ease of portability. Therefore, 
the second part of this research focused on the design and manufacturing of ODMTs.  
According to the published literature, there exists abundant information on oro-dispersible 
tablets, which are simply a large form of ODMTs. However, very few articles were specific to 
ODMTs intended for paediatric use e.g. risperidone oral disintegrating mini-tablets134. In that 
work, 15 risperidone batches were formulated and drug-excipient compatibility assessed 
using FTIR; no drug degradation was observed.  However, with furosemide ODMT 
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formulation, the more accurate method of DSC was used; furosemide showed good 
compatibility with excipients with no sign of degradation. Powder fluidity assessment (angle 
of repose and Hausner’s ratio) for risperidone and furosemide was accepted for all batches 
although risperidone used silicon dioxide glidant and furosemide used magnesium stearate 
lubricant, which has some minor glidant properties. However, powder flow is also dependent 
upon particle/granule size, granule shape, porosity and other mechanical factors such as the 
use of vibratory hoppers. 
Of the 16 batches of furosemide ODMTs manufactured using a Manesty D3 machine only 6 
batches passed the friability test compared to the 15 batches formulated for risperidone in 
which they all passed using Tablet-press II MT. According to publishers, the friability test was 
passed by all batches after a pre-treatment was applied to achieve 5 kN crushing force, which 
means the compression force was altered but its values were not mentioned. The design of 
furosemide experiments led to the selection of batches 1, 5, 11 and 15.  This approach showed 
that increasing lubricant level and furosemide content led to poorer quality tablets when 
evaluated for friability and disintegration properties. These two factors are important as they 
relate to mechanical stability (e.g. handling, transport) and in vivo performance.  
The disintegration time of furosemide ODMT batches varied between 13 - 38 seconds 
whereas with risperidone it ranged between 3 - 103 seconds. However, the disintegrating 
medium used in testing furosemide ODMTs was human saliva in small test tube; where with 
risperidone, skimmed milk was used. The variation in disintegrating time of furosemide 
ODMTs was explained with consideration of the lubricant level and compression force. With 
risperidone ODMTs, different superdisintegrants were used amongst the 15 batches 
(Plasdone XL, Explotab and AC-Disol) what explains the large variation in disintegration times. 
In this research, furosemide ODMTs were packaged and tested for stability under accelerated 
conditions, which showed good stability with no degradation of API. No such studies were 
conducted on risperidone ODMTs and packaging type was not discussed either.  The quality 
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target product profile (QTTP), as part of the Quality-by-Design approach, was partly 
established for furosemide ODMTs. Elements of the QTPP were incorporated in the 
manufacture of batches by using factorial design of experiments approach. 
Overall, there are few limitations encountered with ODMTs. Firstly, high dose content cannot 
be incorporated. To circumvent this multiple number of mini-tablets can be taken, which a 
number of recently published studies have shown to be possible in young children e.g. 3 x 
2mm tablets in a single dosing session135. Secondly, taste can be difficult to mask and for 
ethical reasons palatability testing is difficult to conduct. Thirdly, ODMTs are hygroscopic in 
nature and special packaging is required to ensure physical, chemical and mechanical stability. 
Despite these limitations, and based on the results obtained from furosemide and risperidone 
formulations, it is envisaged that the research described on ODMTs herein can contribute 
towards the development of this age-appropriate dosage form for paediatric patients.  
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Chapter 6 
6. Conclusion and Future Work 
Morphological analysis, as a problem structuring method, is based on the fundamental 
scientific method of alternating between analysis and synthesis phases. Given the large 
number of uncertainties present in the field of paediatric drug development, MA was chosen 
to cycle between the analytical phase of generating and refining the problem space 
(morphological field) and synthetic phase with the CCA processes. It was observed that CCA 
revealed certain conditions or values under one or more parameter that are not constrained 
at all (i.e. no X or P with any other value) thus identifying and removing an artefact in the 
system. 
The application of MA offered the unearthing of new relationships and/or configurations which 
could have been overlooked by other less structured methods. And most importantly as 
indicated in this thesis, it encourages the identification and investigation of boundary 
conditions i.e. the limits and extremes of different contexts and factors found in paediatric drug 
development. 
Overall, MA has definite advantages for scientific investigations by parameterising complex 
problems and finding possible solutions. This is achieved by the participation of stakeholders 
of different scientific background. For example, the method applied in this research demands 
that parameters, conditions and the issues underlying the uncertainties of paediatric 
formulation be clearly defined. Poorly defined parameters become immediately evident when 
they are cross-referenced and assessed for internal consistency (CCA). Additionally, both the 
construction of the morphological field itself and the assessments made in the CCA matrix, 
represent a clear ‘audit trail’, which makes the judgmental processes inherent in MA relatively 
traceable, and in a certain sense even reproducible. 
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Based on the MA solution space, microemulsion as an oral liquid dosage form was considered 
an age-appropriate dosage form for all paediatric age groups. Additionally, according to the 
ADI and NOAEL values and with reference to toxicological data on the excipients used, a non-
toxic paediatric-friendly formulation was thus developed for all paediatric age groups. Full 
studies were conducted to optimise the furosemide microemulsion dosage formulation. These 
studies on microemulsion preparation revealed that the optimal microemulsion formulation 
containing furosemide at 10mg/ml for paediatric oral route of administration could be 
developed using the composition of: 
(MCT Oil 14%, Labrasol 60%-Transcutol-HP 20% (3:1) and Water 6%) 
This composition showed spontaneous emulsification, good thermodynamic stability and drug-
excipient compatibility. The solubility screening studies showed good solubilising capability of 
labrasol surfactant over labrafil surfactant to dissolve sufficiently high concentration of 
furosemide.  
To sum up, the study resulted in the development of a novel microemulsion containing labrasol 
surfactant and transcutol-HP co-surfactant and is believed to be a promising strategy for 
enhancing the solubility and subsequently the oral bioavailability of molecular entities with low 
solubility such as furosemide.  
MA has also revealed orally disintegrating tablet dosage form as a novel age-appropriate 
dosage form that can be administered for infant and children. Orally disintegrating tablets of 
furosemide were successfully developed and formulated in this research. Prior to formulation, 
the selection of excipients was approved after the DSC thermograms indicated good 
compatibility between selected excipients and furosemide API. Pre-compression results 
showed good flowability and compressibility values of powder mixture at low and high 
concentration of magnesium stearate lubricant. Therefore, the total 16 batches resulted from 
factorial design were compressed. After compression, only four batches (1, 5, 11, and 15) 
were found to be acceptable and passed all the post-compression characterisation tests 
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including assay analysis and stability studies. The discarded batches either failed friability or 
weight variation test. However, all batches showed very good wetting and disintegration times 
and the longest were13 and 38 seconds respectively. Based on QTPP design and out of the 
four acceptable batches, batch one failed content acceptability test (> 105%) and the rest 
passed the content analysis test with acceptable dissolution rate. One of these batches was 
packaged and tested for stability and shelf-life studies (Batch 15). Using RP-HPLC, the tablets 
of selected batch remained stable under stress conditions and gave assay values within the 
acceptable range of drug content (95-105%) with no significant decomposition or deterioration 
to furosemide. 
The work carried out in this thesis indicates that MA offers a valuable tool for approaching 
multi-faceted problems. In this case the area of paediatric drug formulation has been looked 
at, suitable formulation approaches have been identified for a specific API and formulations 
have been developed which might be suitable for use. The ability of this system of problem-
solving to incorporate numerical and non-numerical data in reaching decisions as to 
appropriate solutions makes it a useful approach to problems where there are impacts on 
society as well as scientific issues to be considered. MA could therefore have a significant role 
to play in development of drug formulations but also potentially in other areas of 
pharmaceutical and wider medical research.    
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6.1 Practical considerations and future perspectives on the use of morphological 
analysis to develop better medicines for children 
MA, as a problem structuring method, has been shown to be a useful decision-support 
framework, leading to the isolation of a solution space when considering all the uncertain 
variables involved in deciphering the ‘right’ dosage form for paediatrics. However, MA requires 
further validation in terms of using the approach for other medicines for unmet paediatric 
clinical need, for example those listed on the EMA priority list of off-patent drugs used in 
children.   
In addition, and in the context of the described herein, palatability testing of microemulsion 
and ODMT formulation needs to be performed to iteratively improve the MA approach. 
Secondly, extended stability studies need to be conducted for both dosage forms particularly 
for the presence, if any, of impurities that can be derived from the active, furosemide, and/or 
the excipients. Thirdly, the efficacy of furosemide at low doses needs to be assessed in order 
to evaluate the effect of API in clinical trials after enhancing the solubility using. 
Finally, MA approach in paediatric formulation design should be refined and validated by 
involving subject matter specialists through a series of workshops facilitated by a neutral, 
objective facilitator. This can be performed by expanding the subject matter specialists and 
the stake holders lists to assure each parameter of the problem space is defined and the 
cross-consistency is look at after full consideration of entire dimensions.  
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